{"ctNumber":"2025-523264-21-00","ctStatus":"Authorised","startDateEU":"2026-06-04","decisionDate":"2026-01-23T18:35:27.022","publishDate":"2026-06-06T03:31:05.205799916","ctPublicStatusCode":4,"authorizedApplication":{"authorizedPartI":{"id":111323,"rowSubjectCount":0,"products":[{"id":461513,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB194115","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"FLORTAUCIPIR (18F)","pharmForm":"SOLUTION FOR INJECTION","activeSubstanceName":"FLORTAUCIPIR (18F)","euSubstNumber":"SUB194115","productSubstances":[{"substancePk":"338079","actSubstOrigin":"Chemical","actSubstName":"FLORTAUCIPIR (18F)","substanceEvCode":"SUB194115"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"MBq megabecquerel(s)","maxDailyDoseAmount":"370","doseUomTotal":"MBq megabecquerel(s)","maxTotalDoseAmount":"370","productChangedRelationMA":true,"productChangeDescription":"use in volunteers","maxTreatmentPeriod":1,"timeUnitCode":"1","scientificProductEvCode":"SUB194115","devices":[],"characteristics":["3"],"routes":["INTRAVENOUS USE"],"allSubstancesChemicals":false,"productName":"FLORTAUCIPIR (18F)","jsonActiveSubstanceNames":"flortaucipir (18f)"},{"id":461514,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB194115","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"FLORTAUCIPIR (18F)","pharmForm":"SOLUTION FOR INJECTION","activeSubstanceName":"FLORTAUCIPIR (18F)","euSubstNumber":"SUB194115","productSubstances":[{"substancePk":"425488","actSubstOrigin":"Chemical","actSubstName":"FLORTAUCIPIR (18F)","substanceEvCode":"SUB194115"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"MBq megabecquerel(s)","maxDailyDoseAmount":"370","doseUomTotal":"MBq megabecquerel(s)","maxTotalDoseAmount":"370","productChangedRelationMA":true,"productChangeDescription":"use in volunteers","maxTreatmentPeriod":1,"timeUnitCode":"1","scientificProductEvCode":"SUB194115","devices":[],"characteristics":["3"],"routes":["INTRAVENOUS USE"],"allSubstancesChemicals":false,"productName":"FLORTAUCIPIR (18F)","jsonActiveSubstanceNames":"flortaucipir (18f)"},{"id":461516,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB33779","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"FLORBETAPIR (18F)","pharmForm":"SOLUTION FOR INJECTION","activeSubstanceName":"FLORBETAPIR (18F)","euSubstNumber":"SUB33779","productSubstances":[{"substancePk":"157591","actSubstOrigin":"Chemical","actSubstName":"FLORBETAPIR (18F)","substanceEvCode":"SUB33779"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"MBq megabecquerel(s)","maxDailyDoseAmount":"370","maxTotalDoseAmount":"370","productChangedRelationMA":true,"productChangeDescription":"use in volunteers","maxTreatmentPeriod":1,"timeUnitCode":"1","scientificProductEvCode":"SUB33779","devices":[],"characteristics":["3"],"routes":["INTRAVENOUS USE"],"allSubstancesChemicals":false,"productName":"FLORBETAPIR (18F)","jsonActiveSubstanceNames":"florbetapir (18f)"},{"id":461515,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB33779","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"FLORBETAPIR (18F)","pharmForm":"SOLUTION FOR INJECTION","activeSubstanceName":"FLORBETAPIR (18F)","euSubstNumber":"SUB33779","productSubstances":[{"substancePk":"354897","actSubstOrigin":"Chemical","actSubstName":"FLORBETAPIR (18F)","substanceEvCode":"SUB33779"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"MBq megabecquerel(s)","maxDailyDoseAmount":"370","doseUomTotal":"MBq megabecquerel(s)","maxTotalDoseAmount":"370","productChangedRelationMA":true,"productChangeDescription":"use in volunteers","maxTreatmentPeriod":1,"timeUnitCode":"1","scientificProductEvCode":"SUB33779","devices":[],"characteristics":["3"],"routes":["INTRAVENOUS USE"],"allSubstancesChemicals":false,"productName":"FLORBETAPIR (18F)","jsonActiveSubstanceNames":"florbetapir (18f)"}],"trialDetails":{"clinicalTrialIdentifiers":{"fullTitle":"CIRAANO: Multimodal exploration (including radiopharmaceuticals Amyvid® and Tauvid®) of theater actors, memory athletes, and patients with various memory pathologies: evaluation of mnesic strategies and their cerebral substrates, and contribution to the treatment of memory pathologies.","fullTitleTranslations":[{"id":9042088,"uuid":"0f5ef9e6-bf14-4183-94d9-e9dbef350897","attributeTranslation":"Exploration multimodale (comprenant les produits radiopharmaceutiques Amyvid® et Tauvid®) des acteurs de théâtre, des athlètes de la mémoire, et des patients atteints de différentes pathologies de la mémoire : évaluation des stratégies mnésiques et de leurs substrats cérébraux, et apport pour la prise en charge des pathologies de la mémoire","language":34,"languageDescription":"French (France)"}],"publicTitle":"CIRAANO: Multimodal exploration of theater actors, memory athletes, and patients with various memory pathologies: evaluation of mnesic strategies and their cerebral substrates, and contribution to the treatment of memory pathologies.","publicTitleTranslations":[{"id":9042132,"uuid":"c11982cc-cd33-4f7b-8b27-c249a2612367","attributeTranslation":"Exploration multimodale des acteurs de théâtre, des athlètes de la mémoire, et des patients atteints de différentes pathologies de la mémoire : évaluation des stratégies mnésiques et de leurs substrats cérébraux, et apport pour la prise en charge des pathologies de la mémoire","language":34,"languageDescription":"French (France)"}],"shortTitle":"C24-50","secondaryIdentifyingNumbers":{"additionalRegistries":[]}},"trialInformation":{"trialCategory":{"isLowIntervention":false,"trialPhase":"10","trialCategory":"2","justificationForTrialCategory":"physiopathological study using products outside the conditions of their marketing authorization (memory disorders including healthy volunteers)","trialCategoryId":101639},"medicalCondition":{"partIMedicalConditions":[{"id":115505,"medicalCondition":"Semantic Variant Primary Progressive Aphasia","medicalConditionTranslations":[{"id":9042023,"uuid":"aa98693f-d6f9-4a6e-8dc8-21d604e4df9f","attributeTranslation":"Aphasie Primaire Progressive sémantique","language":34,"languageDescription":"French (France)"}],"isConditionRareDisease":false},{"id":115504,"medicalCondition":"Alcohol Use Disorder","medicalConditionTranslations":[{"id":9042022,"uuid":"adf20efe-909a-4cb5-b0ba-e9e5a03dfd16","attributeTranslation":"Troubles de l’Usage d’Alcool","language":34,"languageDescription":"French (France)"}],"isConditionRareDisease":false},{"id":115503,"medicalCondition":"Organic amnesia syndrome","medicalConditionTranslations":[{"id":9042021,"uuid":"1da1aa01-2a39-4562-80ad-17dcf289757a","attributeTranslation":"Syndrome Amnésique organique","language":34,"languageDescription":"French (France)"}],"isConditionRareDisease":false},{"id":115507,"medicalCondition":"Narcolepsy","medicalConditionTranslations":[{"id":9042025,"uuid":"c0873b8e-366d-45a1-ba79-6116751ff953","attributeTranslation":"Narcolepsie","language":34,"languageDescription":"French (France)"}],"isConditionRareDisease":false},{"id":115506,"medicalCondition":"Alzheimer","medicalConditionTranslations":[{"id":9042024,"uuid":"1c97659c-7fb7-4fa6-8539-9d2902efd221","attributeTranslation":"Maladie d'Alzheimer","language":34,"languageDescription":"French (France)"}],"isConditionRareDisease":false},{"id":115508,"medicalCondition":"Lewy Body Dementia","medicalConditionTranslations":[{"id":9042026,"uuid":"ac13f276-312e-4680-a100-06a68763e208","attributeTranslation":"Maladie à Corps de Lewy","language":34,"languageDescription":"French (France)"}],"isConditionRareDisease":false}],"meddraConditionTerms":[{"termId":100000014713,"version":"20.0","level":"PT","termName":"Dementia Alzheimer's type","classificationCode":"10012271","organClass":100000004852,"active":false}]},"trialObjective":{"trialScopes":[{"code":"13","otherDescription":"physiopathological mechanism","trialScopeId":336201}],"mainObjective":"[Part 2] to evaluate, in different categories of patients with memory disorders of various origins, the preservation or alteration of memory-related brain networks, associated with different types of memory strategies identified in memory experts.","mainObjectiveTranslations":[{"id":9042131,"uuid":"f4212ec1-f59e-4a64-b854-433badf030cf","attributeTranslation":"[Partie 2] Evaluer dans différentes catégories de patients atteints de troubles de mémoire d’origines diverses, la préservation ou l’altération des réseaux cérébraux de la mémoire associés à différents types de stratégies mnésiques identifiés chez des experts de la mémoire","language":34,"languageDescription":"French (France)"}],"secondaryObjectives":[{"id":388239,"number":1,"secondaryObjective":"[Part 1 - Objective 1] to assess the feasibility of this trial","secondaryObjectiveTranslations":[{"id":9042133,"uuid":"4b1b7322-2291-49f7-a93e-1a74e1b28b75","attributeTranslation":"[Partie 1 Objectif 1] Evaluer la faisabilité de cette recherche","language":34,"languageDescription":"French (France)"}]},{"id":388240,"number":2,"secondaryObjective":"[Part 1 - Objective 2] to Assess the acceptability of the procedures by participants included in Part 1","secondaryObjectiveTranslations":[{"id":9042134,"uuid":"be9b2e9d-c8ec-4950-9793-750142b031a3","attributeTranslation":"[Partie 1 - Objectif 2] Evaluer l’acceptabilité des examens par les participants inclus dans la partie 1","language":34,"languageDescription":"French (France)"}]},{"id":388241,"number":3,"secondaryObjective":"[Part 2 - Objective 2] To identify the specific characteristics of theatre actors and memory athletes compared to controls, in terms of brain, cognitive, biological, and psycho-affective measures, as well as lifestyle factors, sleep, and alcohol consumption","secondaryObjectiveTranslations":[{"id":9042135,"uuid":"aba0ce27-365b-4302-8b68-03f3467f429d","attributeTranslation":"[Partie 2 - Objectif 2] Mettre en évidence les caractéristiques spécifiques des acteurs de théâtre et des athlètes de la mémoire, par rapport aux contrôles, en termes de mesures cérébrales, cognitives, biologiques, psycho-affectives, de facteurs de style de vie, de sommeil, et de consommation d’alcool","language":34,"languageDescription":"French (France)"}]},{"id":388242,"number":4,"secondaryObjective":"[Part 2 - Objective 3] To identify the specific characteristics of various patient groups with memory disorders of different etiologies, compared to controls, theatre actors, and memory athletes, in terms of brain, cognitive, biological, and psycho-affective measures, lifestyle factors, sleep, and alcohol consumption, as well as inter-individual differences (e.g., related to sex, age, presence of risk factors, etc.)","secondaryObjectiveTranslations":[{"id":9042136,"uuid":"aa81eda7-9429-40c6-be70-7b1d17b2e086","attributeTranslation":"[Partie 2 - Objectif 3] Mettre en évidence les caractéristiques spécifiques des différents groupes de patients présentant des troubles de mémoire d’étiologie distincte, par rapport aux contrôles, aux acteurs de théâtre et aux athlètes de la mémoire appariés pour l’âge, en terme de mesures cérébrales, cognitives, biologiques, psycho-affectives, de facteurs de style de vie, de sommeil, et de consommation d’alcool ; ainsi que les spécificités inter-individuelles (e.g. liées au sexe, à l’âge, à la présence de facteurs de risque, etc.)","language":34,"languageDescription":"French (France)"}]},{"id":388243,"number":5,"secondaryObjective":"[Part 2 - Objective 4] To explore the relationships between brain, biological, cognitive, psycho-affective measures, and lifestyle factors (including sleep and alcohol consumption) across the different groups (controls, actors, memory athletes, and patients), in order to deepen understanding of underlying pathophysiological mechanisms","secondaryObjectiveTranslations":[{"id":9042137,"uuid":"2b0976a0-a29f-40b2-8034-d64d37328a85","attributeTranslation":"[Partie 2 - Objectif 4] Evaluer les liens entre les mesures cérébrales, biologiques, cognitives, psycho-affectives, des facteurs de style de vie, de sommeil, et de consommation d’alcool, dans les différents groupes (contrôles, acteurs, athlètes de la mémoire et patients) pour approfondir notre compréhension des mécanismes physiopathologiques","language":34,"languageDescription":"French (France)"}]},{"id":388244,"number":6,"secondaryObjective":"[Part 2 - Objective 5] To identify the mechanisms driving the topography of brain pathology and the factors influencing its propagation over 10 to 20 years, in both controls and patients, with the aim of predicting disease progression using an artificial intelligence model","secondaryObjectiveTranslations":[{"id":9042138,"uuid":"fabf3f1e-c286-4983-a767-a7c7b2ff2d45","attributeTranslation":"[Partie 2 - Objectif 5] Identifier les mécanismes responsables de la topographie des pathologies des atteintes cérébrales, ainsi que les facteurs déterminants leur propagation sur 10 à 20 ans, chez les contrôles et les patients, pour permettre la prédiction de leur évolution via un modèle d’intelligence artificielle","language":34,"languageDescription":"French (France)"}]}]},"eligibilityCriteria":{"principalInclusionCriteria":[{"id":744509,"number":1,"principalInclusionCriteria":"[all participants] Minimum education level of 7 years (at least equivalent to the French Certificat d’Études Primaires (CEP))","principalInclusionCriteriaTranslations":[{"id":9042089,"uuid":"77bc2403-73e6-40d0-b80c-353a0d759d4b","attributeTranslation":"[Tous les participants] Niveau d’étude ≥ 7 ans (a minima équivalent du Certificat d’Etudes Primaires (CEP))","language":34,"languageDescription":"French (France)"}]},{"id":744510,"number":10,"principalInclusionCriteria":"[HC] Aged 18 or older","principalInclusionCriteriaTranslations":[{"id":9042090,"uuid":"d4bc75a9-668c-4bde-8471-c34700f53f3f","attributeTranslation":"[HC] Âgés de 18 ans ou plus","language":34,"languageDescription":"French (France)"}]},{"id":744511,"number":11,"principalInclusionCriteria":"[HC] Neuropsychological performance within the normal range for age and education level on all inclusion battery tests (±1.65 standard deviation)","principalInclusionCriteriaTranslations":[{"id":9042091,"uuid":"710cddab-2fdc-43bd-b060-24966aafe9ab","attributeTranslation":"[HC] Performances neuropsychologiques dans les normes selon l’âge et le niveau d’études à tous les tests de la batterie d’inclusion (±1,65 écart-type)","language":34,"languageDescription":"French (France)"}]},{"id":744512,"number":12,"principalInclusionCriteria":"[HC] Be considered capable of complying with the protocol according to the investigator's judgment","principalInclusionCriteriaTranslations":[{"id":9042092,"uuid":"f4e58e95-51cf-44fd-aaeb-f29470ceda9f","attributeTranslation":"[HC] Être considéré comme capable de respecter le protocole selon le jugement de l’investigateur","language":34,"languageDescription":"French (France)"}]},{"id":744513,"number":13,"principalInclusionCriteria":"[ATHL] Aged 18 or older","principalInclusionCriteriaTranslations":[{"id":9042093,"uuid":"6e0a11d1-1ff3-4d6e-80de-0ea749b8b198","attributeTranslation":"[ATHL] Âgés de 18 ans ou plus","language":34,"languageDescription":"French (France)"}]},{"id":744514,"number":14,"principalInclusionCriteria":"[ATHL] Must have participated in a memory competition—international, European, or national level","principalInclusionCriteriaTranslations":[{"id":9042094,"uuid":"40397e3b-2f75-477c-a07a-98150e83fe53","attributeTranslation":"[ATHL] Avoir obtenu un score supérieur ou égal à 1500 points lors d’une compétition officielle de la mémoire (https://iam-stats.org/) ou attester de compétences mnésiques équivalentes en obtenant un score d’au moins 27 à l’épreuve « 5-Minute Words »","language":34,"languageDescription":"French (France)"}]},{"id":744515,"number":15,"principalInclusionCriteria":"[ATHL] Be considered capable of complying with the protocol according to the investigator's judgment","principalInclusionCriteriaTranslations":[{"id":9042095,"uuid":"939469e8-2d68-4ded-8bbf-191efd13d603","attributeTranslation":"[ATHL] Être considéré comme capable de respecter le protocole selon le jugement de l’investigateur","language":34,"languageDescription":"French (France)"}]},{"id":744516,"number":16,"principalInclusionCriteria":"[SCD] Aged 60 or older","principalInclusionCriteriaTranslations":[{"id":9042096,"uuid":"126106ac-598b-412c-ba6e-a183aa64f97c","attributeTranslation":"[SCD] Âgés de 60 ans ou plus","language":34,"languageDescription":"French (France)"}]},{"id":744517,"number":17,"principalInclusionCriteria":"[SCD] Recruited from memory clinics","principalInclusionCriteriaTranslations":[{"id":9042097,"uuid":"61b09d5c-d67e-401b-9e0e-09956bf955bf","attributeTranslation":"[SCD] Patients ayant consulté dans les centres de consultation mémoire","language":34,"languageDescription":"French (France)"}]},{"id":744518,"number":18,"principalInclusionCriteria":"[SCD] Must meet recognized criteria for subjective cognitive decline in the context of the preclinical stage of Alzheimer’s disease","principalInclusionCriteriaTranslations":[{"id":9042098,"uuid":"fd406325-3133-41eb-89bc-35d0a454ba5d","attributeTranslation":"[SCD] Répondant aux critères reconnus de déclin cognitif subjectif dans le contexte du stade préclinique de la Maladie d'Alzheimer","language":34,"languageDescription":"French (France)"}]},{"id":744519,"number":19,"principalInclusionCriteria":"[MCI-AD] Aged 60 or older","principalInclusionCriteriaTranslations":[{"id":9042099,"uuid":"f5fca020-0bae-4eb1-a80d-e7e477a938e8","attributeTranslation":"[MCI-AD] Âgés de 60 ans ou plus","language":34,"languageDescription":"French (France)"}]},{"id":744520,"number":2,"principalInclusionCriteria":"[all participants] Native French speaker and educated in French","principalInclusionCriteriaTranslations":[{"id":9042100,"uuid":"45d196e8-33ae-403f-a6e1-9910c3dc83bf","attributeTranslation":"[tous les participants] Francophone et ayant effectué leur scolarité en français","language":34,"languageDescription":"French (France)"}]},{"id":744521,"number":20,"principalInclusionCriteria":"[MCI-AD] Recruited from memory clinics","principalInclusionCriteriaTranslations":[{"id":9042101,"uuid":"d2c5c53b-3269-4db5-b025-318f2d59b0c7","attributeTranslation":"[MCI-AD] Patients ayant consulté dans les centres de consultation mémoire","language":34,"languageDescription":"French (France)"}]},{"id":744522,"number":21,"principalInclusionCriteria":"[MCI-AD] Must meet current recognized clinical criteria for mild cognitive impairment due to Alzheimer’s disease","principalInclusionCriteriaTranslations":[{"id":9042102,"uuid":"57f0e176-ac7c-406f-96fc-9cd56c4465a9","attributeTranslation":"[MCI-AD] Répondant aux critères cliniques actuels et reconnus de troubles cognitifs mineurs dus à une MA (Mild cognitive impairment due to Alzheimer’s disease or MCI due to AD)","language":34,"languageDescription":"French (France)"}]},{"id":744523,"number":22,"principalInclusionCriteria":"[D-AD] Aged 60 years or older","principalInclusionCriteriaTranslations":[{"id":9042103,"uuid":"44acc3ce-3410-49bb-82db-ccf1f90d4b36","attributeTranslation":"[D-AD] Âgés de 60 ans ou plus","language":34,"languageDescription":"French (France)"}]},{"id":744524,"number":23,"principalInclusionCriteria":"[D-AD] Recruited from memory clinics","principalInclusionCriteriaTranslations":[{"id":9042104,"uuid":"ad1dcda5-53b4-4f22-b6cd-0ca8fef7b1df","attributeTranslation":"[D-AD] Patients ayant consulté dans les centres de consultation mémoire","language":34,"languageDescription":"French (France)"}]},{"id":744525,"number":24,"principalInclusionCriteria":"[D-AD] Meeting current and recognized clinical criteria for major neurocognitive disorder due to probable Alzheimer’s disease","principalInclusionCriteriaTranslations":[{"id":9042105,"uuid":"2747193e-74b1-4da8-bc13-581f9afd0c3a","attributeTranslation":"[D-AD] Répondant aux critères cliniques actuels et reconnus de troubles cognitifs majeurs dus à une MA probable","language":34,"languageDescription":"French (France)"}]},{"id":744526,"number":25,"principalInclusionCriteria":"[LBD] Aged 60 years or older","principalInclusionCriteriaTranslations":[{"id":9042106,"uuid":"7d580b40-ba6b-4cfa-8492-c9a4348dc028","attributeTranslation":"[LBD] Âgés de 60 ans ou plus","language":34,"languageDescription":"French (France)"}]},{"id":744527,"number":26,"principalInclusionCriteria":"[LBD] Recruited from memory clinics","principalInclusionCriteriaTranslations":[{"id":9042107,"uuid":"fb8b2892-6b02-48e5-abdd-77eebf9eb0a1","attributeTranslation":"[LBD] Patients ayant consulté dans les centres de consultation mémoire","language":34,"languageDescription":"French (France)"}]},{"id":744528,"number":27,"principalInclusionCriteria":"[LBD] Meeting current and recognized clinical criteria for probable Lewy body dementia or probable prodromal Lewy body dementia (mild cognitive impairment with Lewy bodies)","principalInclusionCriteriaTranslations":[{"id":9042108,"uuid":"49292202-7f42-454c-a258-fd1e3aec830b","attributeTranslation":"[LBD] Répondant aux critères cliniques actuels et reconnus de maladie à corps de Lewy probable ou maladie à corps de Lewy prodromale probable (mild cognitive impairment (MCI) with Lewy body)","language":34,"languageDescription":"French (France)"}]},{"id":744529,"number":28,"principalInclusionCriteria":"[svPPA] Aged 50 years or older","principalInclusionCriteriaTranslations":[{"id":9042109,"uuid":"3ce34083-9280-426a-a38c-9ccab8dfe920","attributeTranslation":"[svPPA] Âgés de 50 ans et plus","language":34,"languageDescription":"French (France)"}]},{"id":744530,"number":29,"principalInclusionCriteria":"[svPPA] Recruited from memory clinics","principalInclusionCriteriaTranslations":[{"id":9042110,"uuid":"848dfa06-a8ea-4e43-b585-f430ada26a4a","attributeTranslation":"[svPPA] Patients ayant consulté dans les centres de consultation mémoire","language":34,"languageDescription":"French (France)"}]},{"id":744531,"number":3,"principalInclusionCriteria":"[all participants] Affiliated with a French social security scheme or beneficiary of such a scheme","principalInclusionCriteriaTranslations":[{"id":9042111,"uuid":"b6d484ef-341c-4b36-8a8c-74956a6b4970","attributeTranslation":"[tous les participants] Affiliation à un régime de sécurité sociale ou bénéficiaire d’un tel régime","language":34,"languageDescription":"French (France)"}]},{"id":744532,"number":30,"principalInclusionCriteria":"[svPPA] Meeting current and recognized clinical criteria for semantic dementia","principalInclusionCriteriaTranslations":[{"id":9042112,"uuid":"752c1eae-8e07-4ffe-84bc-f50c3a338389","attributeTranslation":"[svPPA] Répondant aux critères cliniques actuels et reconnus de démence sémantique","language":34,"languageDescription":"French (France)"}]},{"id":744533,"number":31,"principalInclusionCriteria":"[AUD] Aged 18 years or older","principalInclusionCriteriaTranslations":[{"id":9042113,"uuid":"17e2743f-cf5f-4851-8b2d-4326ea136e9e","attributeTranslation":"[AUD] Âgés de 18 ans ou plus","language":34,"languageDescription":"French (France)"}]},{"id":744534,"number":32,"principalInclusionCriteria":"[AUD] Recruited from an addiction treatment service","principalInclusionCriteriaTranslations":[{"id":9042114,"uuid":"f50e6f79-ae49-47eb-9e4c-23bab5776030","attributeTranslation":"[AUD] Recrutés dans un service d’addictologie","language":34,"languageDescription":"French (France)"}]},{"id":744535,"number":33,"principalInclusionCriteria":"[AUD] Undergoing treatment primarily for an alcohol use disorder at the time of inclusion","principalInclusionCriteriaTranslations":[{"id":9042115,"uuid":"ec374811-ad22-4fb2-b7f6-a5d5ae8a592b","attributeTranslation":"[AUD] Pris en charge pour un AUD au premier plan des troubles de l'usage au moment de l'inclusion","language":34,"languageDescription":"French (France)"}]},{"id":744536,"number":34,"principalInclusionCriteria":"[AUD] Detoxified, with withdrawal symptoms resolved (Cushman score <3, Cushman et al., 1985) and benzodiazepines discontinued at the time of inclusion","principalInclusionCriteriaTranslations":[{"id":9042116,"uuid":"e331c4c3-8238-47cc-b7bc-0b71b91bcc43","attributeTranslation":"[AUD] Sevrés d’alcool, après disparition des signes de sevrage d’alcool (score de Cushman <3, Cushman et al., 1985) et arrêt des benzodiazépines de sevrage au moment de l’inclusion","language":34,"languageDescription":"French (France)"}]},{"id":744537,"number":35,"principalInclusionCriteria":"[AUD] Abstinent from all psychoactive substances (except tobacco and prescribed medication) at the time of inclusion","principalInclusionCriteriaTranslations":[{"id":9042117,"uuid":"d0ba2630-7154-42ac-bc39-7c1ef56b65fc","attributeTranslation":"[AUD] Abstinents de toute substance psychoactive (hors tabac et médicament prescrit) au moment de l’inclusion","language":34,"languageDescription":"French (France)"}]},{"id":744538,"number":36,"principalInclusionCriteria":"[AMN] Aged 18 years or older","principalInclusionCriteriaTranslations":[{"id":9042118,"uuid":"f9bc54ae-87d6-4885-a1df-735a76bde8a5","attributeTranslation":"[AMN] Âgés de 18 ans ou plus","language":34,"languageDescription":"French (France)"}]},{"id":744539,"number":37,"principalInclusionCriteria":"[AMN] Recruited from hospital services or residential facilities housing patients with non-degenerative amnesic syndromes","principalInclusionCriteriaTranslations":[{"id":9042119,"uuid":"7183154e-1c75-44e7-98cf-d5019498d825","attributeTranslation":"[AMN] Recrutés dans les services hospitaliers ou les lieux de vie accueillant des patients ayant un SA non dégénératif","language":34,"languageDescription":"French (France)"}]},{"id":744540,"number":38,"principalInclusionCriteria":"[AMN] Presenting with major cognitive impairment : Characterized primarily by severe episodic memory deficits (anterograde amnesia), possibly associated with retrograde amnesia and/or other impairments ;\tLeading to significant impacts on daily functioning and reduced autonomy ;\tPersistent and stable over time","principalInclusionCriteriaTranslations":[{"id":9042120,"uuid":"60aa535b-4b4b-4dc3-b9c4-697886e8ef39","attributeTranslation":"[AMN] Présentant des troubles cognitifs majeurs :\n- caractérisés par des atteintes sévères de la mémoire épisodique au premier plan (amnésie antérograde), associées ou non à une amnésie rétrograde ou d’autres troubles ; \n- ayant des répercussions significatives dans la vie quotidienne et limitant l’autonomie ;\n- persistants et stabilisés.","language":34,"languageDescription":"French (France)"}]},{"id":744541,"number":39,"principalInclusionCriteria":"[NARCO] Aged 18 years or older","principalInclusionCriteriaTranslations":[{"id":9042121,"uuid":"a04b8901-2781-4943-bb45-5b176d747fa5","attributeTranslation":"[NARCO] Âgés de 18 ans ou plus","language":34,"languageDescription":"French (France)"}]},{"id":744542,"number":4,"principalInclusionCriteria":"[all participants] Willingness to undergo several days of assessments","principalInclusionCriteriaTranslations":[{"id":9042122,"uuid":"fb074aac-b366-4d1c-a0c3-42bb44ae653a","attributeTranslation":"[tous les participants] Être volontaire pour plusieurs jours d'examens","language":34,"languageDescription":"French (France)"}]},{"id":744543,"number":40,"principalInclusionCriteria":"[NARCO] -\tDiagnosed with type 1 narcolepsy according to the 3rd edition of the International Classification of Sleep Disorders (ICSD-3), which includes daytime sleepiness persisting for more than 3 months, and either : Presence of cataplexy, mean sleep latency <8 minutes on the Multiple Sleep Latency Test (MSLT), and at least two REM sleep onsets (on MSLT and/or overnight polysomnography) ;  Or cerebrospinal fluid hypocretin level <110 pg/mL.","principalInclusionCriteriaTranslations":[{"id":9042123,"uuid":"03bc1924-4666-4950-85bf-a520c36360af","attributeTranslation":"[NARCO] Atteints de narcolepsie de type 1 selon les critères de la 3ème édition de la classification internationale des troubles du sommeil (ICSD-3) à savoir la présence d’une somnolence évoluant depuis plus de 3 mois, associée à : \n- soit la présence de cataplexies, d’une latence moyenne d’endormissement de moins de 8 minutes aux tests itératifs de latence d’endormissement (TILE) et d’au moins deux endormissements en sommeil paradoxal (aux TILE et/ou lors d’une polysomnographie nocturne) ;\n- soit un taux d’hypocrétine inférieur à 110 pg/mL dans le liquide céphalorachidien.","language":34,"languageDescription":"French (France)"}]},{"id":744544,"number":41,"principalInclusionCriteria":"[Informant] Aged 18 years or older","principalInclusionCriteriaTranslations":[{"id":9042124,"uuid":"1a912896-8d31-4a06-a96b-748e649b62ae","attributeTranslation":"[Informant] Âgés de 18 ans ou plus","language":34,"languageDescription":"French (France)"}]},{"id":744545,"number":42,"principalInclusionCriteria":"[Informant] Spending at least one day per week with a relative included in one of the patient groups","principalInclusionCriteriaTranslations":[{"id":9042125,"uuid":"74d3a4a6-4d8f-4162-904a-ce61b5f42d19","attributeTranslation":"[Informant] Passant au moins une journée par semaine avec le proche participant à la recherche.","language":34,"languageDescription":"French (France)"}]},{"id":744546,"number":5,"principalInclusionCriteria":"[all participants] Adherence to lifestyle considerations","principalInclusionCriteriaTranslations":[{"id":9042126,"uuid":"46fc7319-8cdb-4b83-97cc-12c3a12b4eff","attributeTranslation":"[tous les participants] Adhésion aux considérations de mode de vie","language":34,"languageDescription":"French (France)"}]},{"id":744547,"number":6,"principalInclusionCriteria":"[all participants] Signed informed consent to participate in the study","principalInclusionCriteriaTranslations":[{"id":9042127,"uuid":"fe8a9559-c935-4e95-aa8f-dfc08f99a05b","attributeTranslation":"[tous les participants] Signature du consentement éclairé de participation au protocole","language":34,"languageDescription":"French (France)"}]},{"id":744548,"number":7,"principalInclusionCriteria":"[ACT] Aged 18 or older","principalInclusionCriteriaTranslations":[{"id":9042128,"uuid":"d458bcf7-eb3f-4fd6-92cb-7a428599185d","attributeTranslation":"[ACT] Âgés de 18 ans ou plus","language":34,"languageDescription":"French (France)"}]},{"id":744549,"number":8,"principalInclusionCriteria":"[ACT] Must have performed in at least one theatre play in the last three years","principalInclusionCriteriaTranslations":[{"id":9042129,"uuid":"14b3a193-7700-4c58-853c-8f4ea46ac80d","attributeTranslation":"[ACT] Avoir joué au moins une pièce de théâtre sur les 3 dernières années","language":34,"languageDescription":"French (France)"}]},{"id":744550,"number":9,"principalInclusionCriteria":"[ACT] Must be or have been a professional actor, either freelance or permanent (e.g., in a theatre company or at the Comédie-Française) for at least 5 years","principalInclusionCriteriaTranslations":[{"id":9042130,"uuid":"b6033005-e18a-4294-8532-af6773bf2f57","attributeTranslation":"[ACT] Être ou avoir été acteurs intermittents du spectacle ou permanent (dans une compagnie ou à la Comédie-Française par exemple) pendant au moins 5 ans","language":34,"languageDescription":"French (France)"}]}],"principalExclusionCriteria":[{"id":1276745,"number":1,"principalExclusionCriteria":"[all participants except informants] Pregnant or breastfeeding women","principalExclusionCriteriaTranslations":[{"id":9042057,"uuid":"cd595e36-756a-47aa-842c-9c96d1c99d69","attributeTranslation":"[Tous les participants hors informant] Femmes enceintes et femmes allaitantes","language":34,"languageDescription":"French (France)"}]},{"id":1276756,"number":10,"principalExclusionCriteria":"[all participants except informants] Presence of contraindications to MRI (e.g., claustrophobia, ferromagnetic objects in the body) or to Amyvid® and Tauvid® PET scans.","principalExclusionCriteriaTranslations":[{"id":9042068,"uuid":"335272cd-a6a4-4d8a-bb41-1eadd066a03a","attributeTranslation":"[Tous les participants hormis les informants] Présence de contre-indications à l’examen IRM (claustrophobie, objet ferromagnétique dans le corps ; cf liste en annexe) ou à la TEP Amyvid® et Tauvid®","language":34,"languageDescription":"French (France)"}]},{"id":1276757,"number":11,"principalExclusionCriteria":"[SCD] Presence of depressive symptoms (MADRS score > 34, threshold for severe depression)","principalExclusionCriteriaTranslations":[{"id":9042069,"uuid":"3ceee74a-4baf-4232-bee9-2798c1b1aaa7","attributeTranslation":"[SCD] Présence de symptomatologie dépressive (score > 34 à l’échelle MADRS, seuil de dépression sévère)","language":34,"languageDescription":"French (France)"}]},{"id":1276758,"number":12,"principalExclusionCriteria":"[MCI-AD] Presence of depressive symptoms (MADRS score > 34, threshold for severe depression)","principalExclusionCriteriaTranslations":[{"id":9042070,"uuid":"fd3869b9-bb77-4d62-9adb-0bf73b3f062b","attributeTranslation":"[MCI-AD] Présence de symptomatologie dépressive (score > 34 à l’échelle MADRS, seuil de dépression sévère)","language":34,"languageDescription":"French (France)"}]},{"id":1276759,"number":13,"principalExclusionCriteria":"[MCI-AD] Use of Alzheimer’s disease medications (including but not limited to donepezil, rivastigmine, galantamine, and memantine) at non-stabilized doses within 8 weeks prior to the inclusion visit","principalExclusionCriteriaTranslations":[{"id":9042071,"uuid":"53863949-685c-45e1-b95c-d5a1b364b9e6","attributeTranslation":"[MCI-AD] Utilisation de médicaments contre la MA (y compris mais sans s’y limiter, le donépézil, la rivastigmine, la galantamine et la mémantine) à des doses non stabilisées au moins 8 semaines précédant la visite d’inclusion","language":34,"languageDescription":"French (France)"}]},{"id":1276760,"number":14,"principalExclusionCriteria":"[D-AD, LBD & svPPA] Presence of depressive symptoms (MADRS score > 34, threshold for severe depression)","principalExclusionCriteriaTranslations":[{"id":9042072,"uuid":"6fb502e6-d585-4141-837d-058907220029","attributeTranslation":"[D-AD, LBD & svPPA] Présence de symptomatologie dépressive (score > 34 à l’échelle MADRS, seuil de dépression sévère)","language":34,"languageDescription":"French (France)"}]},{"id":1276761,"number":15,"principalExclusionCriteria":"[D-AD, LBD & svPPA] Absence of a caregiver or informant (i.e., a trusted person or relative who will be present from inclusion through the assessments, for patients with major cognitive impairment)","principalExclusionCriteriaTranslations":[{"id":9042073,"uuid":"9b61a54a-2373-4d5f-95c4-9e93bb1adaca","attributeTranslation":"[D-AD, LBD & svPPA] Absence d’un accompagnant (i.e. personne de confiance, proche du patient qui sera présent de l’inclusion jusqu’à la réalisation des examens, pour les patients avec troubles cognitifs majeurs)","language":34,"languageDescription":"French (France)"}]},{"id":1276762,"number":16,"principalExclusionCriteria":"[D-AD, LBD & svPPA] Use of Alzheimer’s disease medications (including but not limited to donepezil, rivastigmine, galantamine, and memantine) and/or L-DOPA for LBD patients, at non-stabilized doses within 8 weeks prior to the inclusion visit","principalExclusionCriteriaTranslations":[{"id":9042074,"uuid":"fdae9510-4805-4b51-82c2-417f5547488a","attributeTranslation":"[D-AD, LBD & svPPA] Utilisation de médicaments contre la MA (y compris mais sans s’y limiter, le donépézil, la rivastigmine, la galantamine et la mémantine) et/ou L-DOPA pour les patients LBD, à des doses non stabilisées au moins 8 semaines précédant la visite d’inclusion","language":34,"languageDescription":"French (France)"}]},{"id":1276763,"number":17,"principalExclusionCriteria":"[D-AD, LBD & svPPA] Inability to understand instructions","principalExclusionCriteriaTranslations":[{"id":9042075,"uuid":"a029d93c-7512-4d4e-9358-a3667a413e1e","attributeTranslation":"[D-AD, LBD & svPPA] Incompréhension des consignes","language":34,"languageDescription":"French (France)"}]},{"id":1276764,"number":18,"principalExclusionCriteria":"[AUD & AMN] Presence of depressive symptoms (MADRS score > 34, threshold for severe depression)","principalExclusionCriteriaTranslations":[{"id":9042076,"uuid":"0adce671-8014-44f4-b15c-b5b9c322f8e8","attributeTranslation":"[AUD & AMN] Présence de symptomatologie dépressive (score > 34 à l’échelle MADRS, seuil de dépression sévère)","language":34,"languageDescription":"French (France)"}]},{"id":1276765,"number":19,"principalExclusionCriteria":"[AUD & AMN] Evidence suggesting a probable neurodegenerative disorder (e.g., impairment in instrumental cognitive functions)","principalExclusionCriteriaTranslations":[{"id":9042077,"uuid":"6ce1668d-deb8-4956-b5fc-de346d2c8d98","attributeTranslation":"[AUD & AMN] Arguments en faveur d’une pathologie neurodégénérative cliniquement probable (troubles des fonctions instrumentales par exemple)","language":34,"languageDescription":"French (France)"}]},{"id":1276746,"number":2,"principalExclusionCriteria":"[all participants except informants] Chronic use of medications that affect cognition and/or may interfere with cognitive or imaging assessments (including non-tricyclic antidepressants, anticonvulsants such as lamotrigine, pregabalin, levetiracetam ; atypical antipsychotics; short-/intermediate-acting benzodiazepines such as alprazolam, lorazepam, oxazepam, temazepam; and sedative antihistamines), if doses were not stabilized within the 6 weeks prior to inclusion (except for changes due to withdrawal treatment in AUD patients)","principalExclusionCriteriaTranslations":[{"id":9042058,"uuid":"c5041875-16e6-4e3e-8b25-c5e7ba2a8cb6","attributeTranslation":"[Tous les participants hormis les informants] Utilisation chronique de traitements qui affectent la cognition et/ou susceptibles d’interférer avec les mesures cognitives ou d’imagerie (antidépresseurs autres que tricycliques), anticonvulsivants (tels que lamotrigine, prégabaline, levetiracetam), antipsychotiques atypiques, benzodiazépines à courte/moyenne durée d’action (y compris alprazolam, lorazepam, oxazepam, temazepam), antihistaminiques à action sédative, à des doses non stabilisées dans les 6 semaines précédant la visite d’inclusion et donc l’inclusion (hormis modifications des prescriptions liées au sevrage pour les patients AUD)","language":34,"languageDescription":"French (France)"}]},{"id":1276767,"number":20,"principalExclusionCriteria":"[all participants except informants] Known hypersensitivity to Amyvid® or Tauvid®","principalExclusionCriteriaTranslations":[{"id":9042079,"uuid":"8fe58bbe-18a9-4a88-876a-1509a50721fc","attributeTranslation":"[Tous les participants hormis les informants] Hypersensibilité connue à l'Amyvid® ou Tauvid®","language":34,"languageDescription":"French (France)"}]},{"id":1276768,"number":21,"principalExclusionCriteria":"[NARCO] Presence of depressive symptoms (MADRS score > 34, threshold for severe depression)","principalExclusionCriteriaTranslations":[{"id":9042080,"uuid":"b83222c2-da57-43c0-bf9c-8031428450ca","attributeTranslation":"[NARCO] Présence de symptomatologie dépressive (score > 34 à l’échelle MADRS, seuil de dépression sévère)","language":34,"languageDescription":"French (France)"}]},{"id":1276770,"number":22,"principalExclusionCriteria":"[all participants except informants] Participation in a clinical study involving exposure to ionizing radiation within the year prior to inclusion","principalExclusionCriteriaTranslations":[{"id":9042082,"uuid":"5f18aef6-e6e5-4a12-b76f-5e340a2384b7","attributeTranslation":"[Tous les participants hormis les informants] Participation à une étude clinique impliquant un contact avec des rayonnements ionisants dans l’année précédant l’inclusion","language":34,"languageDescription":"French (France)"}]},{"id":1276771,"number":23,"principalExclusionCriteria":"[all participants except informants] Current participation in a clinical trial and/or other research involving human participants (RIPH) if it includes imaging examinations using radiotracers","principalExclusionCriteriaTranslations":[{"id":9042083,"uuid":"56f2767a-7316-4020-b017-85a4294b0151","attributeTranslation":"[Tous les participants hormis les informants] Inclusion actuelle dans un essai thérapeutique et/ou dans un autre protocole de recherche impliquant la personne humaine (RIPH) si celui-ci comprend des examens d’imagerie utilisant des radiomarqueurs","language":34,"languageDescription":"French (France)"}]},{"id":1276772,"number":24,"principalExclusionCriteria":"[all participants except informants] History of neurological or neurosurgical conditions that could significantly affect cognitive function and/or neuroimaging (e.g., head trauma with loss of consciousness >30 minutes, stroke, multiple sclerosis, insulin coma)","principalExclusionCriteriaTranslations":[{"id":9042084,"uuid":"8acbf128-92a6-43bb-ba3d-11a7d5a8a884","attributeTranslation":"[Tous les participants hormis les informants] Antécédents neurologiques et neuro-chirurgicaux pouvant avoir un retentissement significatif sur le fonctionnement cognitif et/ou les mesures de neuroimagerie (traumatisme crânien avec perte de connaissance > 30 min, AVC, sclérose en plaques, coma insulinique…)","language":34,"languageDescription":"French (France)"}]},{"id":1276773,"number":25,"principalExclusionCriteria":"[all participants except informants] Schizophrenia, psychotic disorders, or bipolar disorders (according to DSM-5 criteria)","principalExclusionCriteriaTranslations":[{"id":9042085,"uuid":"cc27da3d-65f5-443b-95ce-610d9dbf69c6","attributeTranslation":"[Tous les participants hormis les informants] Schizophrénie, trouble psychotique, troubles bipolaires (critères du DSM-5)","language":34,"languageDescription":"French (France)"}]},{"id":1276774,"number":26,"principalExclusionCriteria":"[all participants except informants] Having a score suggesting an alcohol dependence (>9) on the FACE questionnaire (except for AUD patients)","principalExclusionCriteriaTranslations":[{"id":9042086,"uuid":"6e8b3cb6-7da2-40c4-a46c-65b4423c0cf7","attributeTranslation":"[Tous les participants hormis les informants] Avoir un score suggérant une dépendance à l’alcool (>9) au questionnaire FACE (sauf pour patients AUD)","language":34,"languageDescription":"French (France)"}]},{"id":1276775,"number":27,"principalExclusionCriteria":"[all participants except informants] Presence of untreated chronic or acute illnesses (respiratory, cardiovascular, gastrointestinal, renal, metabolic, hematologic, endocrine, or infectious)","principalExclusionCriteriaTranslations":[{"id":9042087,"uuid":"ba92ee93-51c3-42aa-b4a9-67dc1abd2cd6","attributeTranslation":"[Tous les participants hormis les informants] Présence d’une maladie chronique ou aiguë non traitée (respiratoire, cardiovasculaire, digestive, rénale, métabolique, hématologique, endocrinienne ou infectieuse)","language":34,"languageDescription":"French (France)"}]},{"id":1276747,"number":3,"principalExclusionCriteria":"[all participants except informants] Current use of long-acting benzodiazepines, typical antipsychotics, tricyclic antidepressants, or first-generation antihistamines at the time of inclusion (unless related to withdrawal treatment in AUD patients), with discontinuation of such medication less than 3 months prior to inclusion","principalExclusionCriteriaTranslations":[{"id":9042059,"uuid":"71e82f7b-7ddf-4de2-9f91-9a1541fb072d","attributeTranslation":"[Tous les participants hormis les informants] Utilisation actuelle de benzodiazépines à longue durée d’action, antipsychotiques typiques, antidépresseurs tricycliques, antihistaminiques de première génération au moment de l’inclusion (hormis prescriptions liées au sevrage pour les patients AUD) avec un arrêt depuis au moins 3 mois de ce type de prescription","language":34,"languageDescription":"French (France)"}]},{"id":1276748,"number":4,"principalExclusionCriteria":"[all participants except informants] Physical, behavioral, or geographical limitations preventing participation in the study","principalExclusionCriteriaTranslations":[{"id":9042060,"uuid":"fd7a7601-ded6-4d89-a260-a72aa27753ea","attributeTranslation":"[Tous les participants hormis les informants] Impossibilité physique, comportementale ou géographique de participation à l’ensemble des visites protocolaires","language":34,"languageDescription":"French (France)"}]},{"id":1276749,"number":5,"principalExclusionCriteria":"[all participants except informants] Refusal to cooperate during assessments","principalExclusionCriteriaTranslations":[{"id":9042061,"uuid":"54e9a740-655a-4faf-b5c0-f5129fafbaa9","attributeTranslation":"[Tous les participants hormis les informants] Personnes faisant l’objet d’une mesure de sauvegarde de justice","language":34,"languageDescription":"French (France)"}]},{"id":1276751,"number":6,"principalExclusionCriteria":"[HC] Current or recent (within the last 5 years) theater practice","principalExclusionCriteriaTranslations":[{"id":9042063,"uuid":"3446b9b2-6347-436b-9b92-cb5f5cb438a1","attributeTranslation":"[HC] Pratique de théâtre actuelle et dans les 5 dernières années","language":34,"languageDescription":"French (France)"}]},{"id":1276752,"number":7,"principalExclusionCriteria":"[HC] Presence of depressive symptoms (MADRS score > 19, threshold for moderate depression)","principalExclusionCriteriaTranslations":[{"id":9042064,"uuid":"2500f620-116a-4006-bdc4-d058c19503c9","attributeTranslation":"[HC] Présence de symptomatologie dépressive (score > 19 à l’échelle MADRS, seuil de dépression modérée)","language":34,"languageDescription":"French (France)"}]},{"id":1276754,"number":8,"principalExclusionCriteria":"[ACT & ATHL] Presence of depressive symptoms (MADRS score > 19, threshold for moderate depression)","principalExclusionCriteriaTranslations":[{"id":9042066,"uuid":"e6fe052f-fdf8-4a4e-8e7e-6d71cbbe1b93","attributeTranslation":"[ACT & ATHL] Présence de symptomatologie dépressive (score > 19 à l’échelle MADRS, seuil de dépression modérée)","language":34,"languageDescription":"French (France)"}]},{"id":1276755,"number":9,"principalExclusionCriteria":"[ACT & ATHL] Use of Alzheimer’s disease medications (including but not limited to donepezil, rivastigmine, galantamine, and memantine) at non-stabilized doses within 8 weeks prior to the inclusion visit","principalExclusionCriteriaTranslations":[{"id":9042067,"uuid":"5981aa4d-02ac-4bc5-88a3-73a9002cb0de","attributeTranslation":"[ACT & ATHL] Utilisation de médicaments contre la MA (y compris mais sans s’y limiter, le donépézil, la rivastigmine, la galantamine et la mémantine) à des doses non stabilisées au moins 8 semaines précédant la visite d’inclusion","language":34,"languageDescription":"French (France)"}]}]},"endPoint":{"primaryEndPoints":[{"id":871640,"number":1,"endPoint":"[Part 2 - Objective 1] Volume measurements (from T1 MRI) and perfusion measurements (from early-phase Amyvid® PET) in the 4 brain networks in each patient group and in controls","isPrimary":true,"endPointTranslations":[{"id":9042027,"uuid":"b49fab8d-90f2-4f2c-b563-037af39a794d","attributeTranslation":"[Partie 2 - Objectif 1] Mesures de volume (à partir de l’IRM T1) et de perfusion (à partir de la TEP-Amyvid® early) dans les 4 réseaux cérébraux dans chaque groupe de patients et chez les contrôles","language":34,"languageDescription":"French (France)"}]}],"secondaryEndPoints":[{"id":871641,"number":1,"endPoint":"[Part 1 - Objective 1] Number of participants having successfully completed all examinations necessary for the evaluation of the main judgement criterion of CIRAANO","isPrimary":false,"endPointTranslations":[{"id":9042028,"uuid":"de18e6fd-4bf9-4c08-a9e6-f44da20d41a4","attributeTranslation":"[Partie 1 - Objectif 1] Nombre de participants sur 12 inclus, ayant effectué la totalité des examens nécessaires pour répondre à l’objectif principal de CIRAANO selon leurs catégories","language":34,"languageDescription":"French (France)"}]},{"id":871642,"number":2,"endPoint":"[Part 1 - Objective 2] Score obtained on the acceptability scale","isPrimary":false,"endPointTranslations":[{"id":9042029,"uuid":"1d8cef1c-02f9-43a3-921b-c6f342df0945","attributeTranslation":"[Partie 1 - objectif 2] Score obtenu à l’échelle d’acceptabilité","language":34,"languageDescription":"French (France)"}]},{"id":871643,"number":3,"endPoint":"Behavioral data collected using the various questionnaires","isPrimary":false,"endPointTranslations":[{"id":9042030,"uuid":"14cfeb6d-787d-4825-8903-aea820c0d95b","attributeTranslation":"Données comportementales recueillies à l’aide des différents questionnaires et entretiens","language":34,"languageDescription":"French (France)"}]},{"id":871644,"number":4,"endPoint":"Raw scores from neuropsychological tests","isPrimary":false,"endPointTranslations":[{"id":9042031,"uuid":"9ed0cd67-755b-4719-92c4-cbaae870c7c5","attributeTranslation":"Scores bruts issus des tests neuropsychologiques","language":34,"languageDescription":"French (France)"}]},{"id":871645,"number":5,"endPoint":"Scores from the directed forgetting task (number of “To Remember” and “To Forget” words identified as new or previously seen)","isPrimary":false,"endPointTranslations":[{"id":9042032,"uuid":"96e29166-c9a9-477b-86e7-5c34ab21ece6","attributeTranslation":"Scores à la tâche d’oubli dirigé (nombre de mots “A retenir” et “A oublier” identifiés comme nouveaux et déjà vus)","language":34,"languageDescription":"French (France)"}]},{"id":871646,"number":6,"endPoint":"Composite scores by cognitive function and domain (lifestyle factors, sleep, psycho-affective or subjective evaluation) assessed by neuropsychological tests and questionnaires. Composite scores correspond to an average of standardized z-scores, calculated from the raw scores collected in the control group for the corresponding function (scores presenting a normal distribution and without floor/ceiling effects)","isPrimary":false,"endPointTranslations":[{"id":9042033,"uuid":"ec2cf8ec-92e8-4671-b706-b830ff541088","attributeTranslation":"Scores composites par fonction cognitive et domaine (de facteur de vie, de sommeil, psycho-affectif ou d’évaluation subjective) évalués par les tests neuropsychologiques et les questionnaires. Les scores composites correspondent à une moyenne de z-scores standardisés, calculés à partir des scores bruts recueillis chez le groupe contrôle pour la fonction correspondante (scores présentant une distribution normale et sans effet plancher/plafond)","language":34,"languageDescription":"French (France)"}]},{"id":871647,"number":7,"endPoint":"Ranking position in the national memory sports classification (for the memory athlete group)","isPrimary":false,"endPointTranslations":[{"id":9042034,"uuid":"3a233935-9fb8-4299-980f-3587c9b3a342","attributeTranslation":"Position dans le classement national des sports de la mémoire (pour le groupe athlètes de la mémoire)","language":34,"languageDescription":"French (France)"}]},{"id":871648,"number":8,"endPoint":"Theater experience and practice, in terms of time and number of plays learned (for the actor group)","isPrimary":false,"endPointTranslations":[{"id":9042035,"uuid":"11106806-bccb-4aa9-9516-eff344b3a3a0","attributeTranslation":"Expérience et pratique du théâtre, en termes de temps et de nombre de pièces apprises (pour le groupe acteur)","language":34,"languageDescription":"French (France)"}]},{"id":871649,"number":9,"endPoint":"Gray matter volume measured in each voxel of the brain","isPrimary":false,"endPointTranslations":[{"id":9042036,"uuid":"a56ec899-5831-4a45-83d4-ddd1a96c1e42","attributeTranslation":"Volume de substance grise mesuré dans chaque voxel du cerveau","language":34,"languageDescription":"French (France)"}]},{"id":871650,"number":10,"endPoint":"Volume of the hippocampus and hippocampal subfields","isPrimary":false,"endPointTranslations":[{"id":9042037,"uuid":"7399f228-bf9f-47d7-a450-b57ec7405a38","attributeTranslation":"Volume de l’hippocampe et des sous-champs hippocampiques","language":34,"languageDescription":"French (France)"}]},{"id":871651,"number":11,"endPoint":"Volume of the thalamus and thalamic subregions","isPrimary":false,"endPointTranslations":[{"id":9042038,"uuid":"83ca207f-5acf-42d3-b429-df4a99a26e2b","attributeTranslation":"Volume du thalamus et des sous-régions du thalamus","language":34,"languageDescription":"French (France)"}]},{"id":871652,"number":12,"endPoint":"Mean intensity value of the locus coeruleus","isPrimary":false,"endPointTranslations":[{"id":9042039,"uuid":"73dcfffd-e7dc-435d-b3fd-539a2b10a679","attributeTranslation":"Valeur d’intensité moyenne des locus coeruleus","language":34,"languageDescription":"French (France)"}]},{"id":871653,"number":13,"endPoint":"Cerebral perfusion measured in each voxel of the brain","isPrimary":false,"endPointTranslations":[{"id":9042040,"uuid":"de508cd9-91e9-4da5-962f-ba714e796fa7","attributeTranslation":"Perfusion cérébrale mesurée dans chaque voxel du cerveau","language":34,"languageDescription":"French (France)"}]},{"id":871654,"number":14,"endPoint":"Fractional anisotropy, mean diffusivity, and mean kurtosis in each voxel of the brain","isPrimary":false,"endPointTranslations":[{"id":9042041,"uuid":"fc7a6302-76df-4a9e-8096-ac4272feb358","attributeTranslation":"Anisotropie fractionnelle, diffusivité moyenne et Kurtosis moyen dans chaque voxel du cerveau","language":34,"languageDescription":"French (France)"}]},{"id":871655,"number":15,"endPoint":"Number, size, and location of white matter lesions","isPrimary":false,"endPointTranslations":[{"id":9042042,"uuid":"bc1111ba-d13c-444b-ab99-f2c141d28f01","attributeTranslation":"Nombre, taille et localisation des lésions de la substance blanche","language":34,"languageDescription":"French (France)"}]},{"id":871656,"number":16,"endPoint":"Functional brain connectivity","isPrimary":false,"endPointTranslations":[{"id":9042043,"uuid":"9a546e03-bf7a-4382-846e-53e956943375","attributeTranslation":"Connectivité cérébrale fonctionnelle","language":34,"languageDescription":"French (France)"}]},{"id":871657,"number":17,"endPoint":"Beta-amyloid burden (from the radiopharmaceutical Amyvid®) measured in each voxel of the brain and overall mean in gray matter","isPrimary":false,"endPointTranslations":[{"id":9042044,"uuid":"846d3d07-2e38-4af9-b97f-cc6316c2057c","attributeTranslation":"Charge bêta-amyloïde (du radiopharmarceutique Amyvid®) mesurée dans chaque voxel du cerveau et moyenne globale dans la substance grise","language":34,"languageDescription":"French (France)"}]},{"id":871658,"number":18,"endPoint":"Burden of neurofibrillary tangles or abnormally phosphorylated Tau protein (from the radiopharmaceutical Tauvid®) measured in each voxel of the brain and overall mean in the temporal region","isPrimary":false,"endPointTranslations":[{"id":9042045,"uuid":"63fd8e82-9c15-442c-88f8-6b878cff8403","attributeTranslation":"Charge en dégénérescences neurofibrillaires ou protéine Tau anormalement phosphorylées (du radiopharmaceutique Tauvid®) mesurée dans chaque voxel du cerveau et moyenne globale dans la région temporale","language":34,"languageDescription":"French (France)"}]},{"id":871659,"number":19,"endPoint":"Brain activity measured by fMRI specifically associated with recall, encoding, and learning from the text learning task (compared to activity measured during control tasks of reading and verbal articulation)","isPrimary":false,"endPointTranslations":[{"id":9042046,"uuid":"4f5539f7-05a9-4f8a-9bfb-8d285fbbc755","attributeTranslation":"Activité cérébrale mesurée en IRMf associée spécifiquement au rappel, à l’encodage et à l’apprentissage à partir de la tâche d’apprentissage de texte (comparées à l’activité mesurée lors des tâches contrôles de lecture et d’articulation verbale)","language":34,"languageDescription":"French (France)"}]},{"id":871660,"number":20,"endPoint":"Data collected during EEG recording associated with the passive listening task of auditory stimuli","isPrimary":false,"endPointTranslations":[{"id":9042047,"uuid":"ccc3e82f-569d-4525-bc42-caa333b180f5","attributeTranslation":"Données recueillies lors de l’enregistrement EEG associé à la tâche d’écoute passive de stimuli sonores","language":34,"languageDescription":"French (France)"}]},{"id":871661,"number":21,"endPoint":"Spontaneous oscillatory activity (EEG) in a resting state","isPrimary":false,"endPointTranslations":[{"id":9042048,"uuid":"7556a216-a079-4546-a2d1-98bd14894302","attributeTranslation":"Activité oscillatoire spontanée (EEG) dans un état de repos","language":34,"languageDescription":"French (France)"}]},{"id":871662,"number":22,"endPoint":"Subjective sleep measures collected through sleep questionnaires","isPrimary":false,"endPointTranslations":[{"id":9042049,"uuid":"a1d1b566-074c-4f98-aac0-90afd1b17026","attributeTranslation":"Mesures subjectives du sommeil recueillies par les questionnaires de sommeil","language":34,"languageDescription":"French (France)"}]},{"id":871663,"number":23,"endPoint":"Data collected through actigraphy","isPrimary":false,"endPointTranslations":[{"id":9042050,"uuid":"f781605c-29bd-455b-9aa9-829adb1fafc8","attributeTranslation":"Données recueillies grâce à l’actimétrie","language":34,"languageDescription":"French (France)"}]},{"id":871664,"number":24,"endPoint":"Data collected through polysomnographic recordings","isPrimary":false,"endPointTranslations":[{"id":9042051,"uuid":"c7e00a1b-f32b-4f4f-bf7e-9aa3c93ef1e6","attributeTranslation":"Données recueillies grâce aux enregistrements polysomnographiques","language":34,"languageDescription":"French (France)"}]},{"id":871665,"number":25,"endPoint":"Data collected through the SomnoArt® device","isPrimary":false,"endPointTranslations":[{"id":9042052,"uuid":"db08ee51-7066-4ea9-a053-6bfba6462353","attributeTranslation":"Données recueillies grâce au dispositif SomnoArt®","language":34,"languageDescription":"French (France)"}]},{"id":871666,"number":26,"endPoint":"Blood measures","isPrimary":false,"endPointTranslations":[{"id":9042053,"uuid":"ea371fa1-8ce2-40d0-b355-f7e26f26000f","attributeTranslation":"Mesures sanguines","language":34,"languageDescription":"French (France)"}]},{"id":871667,"number":27,"endPoint":"Anthropometric and physical measures (from the medical interview, ECG analysis from polysomnographic recording during a wakeful state)","isPrimary":false,"endPointTranslations":[{"id":9042054,"uuid":"4f7dd375-c5aa-4a62-ba41-5661590f1481","attributeTranslation":"Mesures anthropométriques et physiques (issues de l’entretien médical, de l’analyse ECG de l’enregistrement polysomnographique pendant un enregistrement à l’éveil)","language":34,"languageDescription":"French (France)"}]},{"id":871668,"number":28,"endPoint":"Measurement of liver fibrosis using Fibroscan®","isPrimary":false,"endPointTranslations":[{"id":9042055,"uuid":"4882edf7-91fa-4fe1-8d4e-8370dc5bf4cb","attributeTranslation":"Mesure de la fibrose hépatique grâce au Fibroscan®","language":34,"languageDescription":"French (France)"}]},{"id":871669,"number":29,"endPoint":"Scores from questionnaires and information about the relative (age, type of relationship with the participant, frequency of meetings, number of years of relationship) provided by the accompanying persons/informants depending on the participant’s group","isPrimary":false,"endPointTranslations":[{"id":9042056,"uuid":"69db8de8-96d7-4829-b0c8-b11731f14bbe","attributeTranslation":"Scores issus des questionnaires et informations sur le proche (âge, nature du lien avec le participant, fréquence des rencontres, nombre d’années de relation) proposés aux accompagnants/informants selon le groupe du participant","language":34,"languageDescription":"French (France)"}]}]},"trialDuration":{"estimatedEndDate":"2036-03-01","estimatedRecruitmentStartDate":"2025-11-01"},"sourceOfMonetarySupport":[],"populationOfTrialSubjects":{"ageRanges":[{"id":305668,"ageRangeCategoryCode":"4","ageRangeCategory":"4"},{"id":305667,"ageRangeCategoryCode":"3","ageRangeCategory":"3"}],"ageRangeSecondaryIds":[],"clinicalTrialGroups":[{"code":"2","name":"Patients"},{"code":"1","name":"Healthy volunteers"}],"isFemaleSubjects":true,"isMaleSubjects":true,"isVulnerablePopulationSelected":false},"individualParticipantData":{"planToShareIPD":"1","planDescription":"Systematic individual participant sharing data is not planned, but all requests for the trial’s data will be considered by the sponsor."}},"protocolInformation":{"studyDesign":{"periodDetails":[]}},"scientificAdviceAndPip":{"scientificAdvices":[],"paediatricInvestigationPlan":[]},"associatedClinicalTrials":[],"references":[{"id":470719,"number":"PMID 28592453"},{"id":470701,"number":"PMID 33986301"},{"id":470760,"number":"PMID 35841910"},{"id":470749,"number":"PMID 20592579"},{"id":470754,"number":"PMID 20212064"},{"id":470707,"number":"PMID 20046194"},{"id":470755,"number":"PMID 29504542"},{"id":470770,"number":"PMID 11413257"},{"id":470711,"number":"PMID 24179859"},{"id":470695,"number":"PMID 24304757"},{"id":470780,"number":"PMID 29901881"},{"id":470747,"number":"PMID 34560904"},{"id":470703,"number":"PMID 24846773"},{"id":470789,"number":"PMID 36653245"},{"id":470746,"number":"PMID 14694035"},{"id":470796,"number":"PMID 33100995"},{"id":470790,"number":"PMID 19779148"},{"id":470708,"number":"PMID 35575089"},{"id":470776,"number":"PMID 28757454"},{"id":470806,"number":"PMID 22119654"},{"id":470773,"number":"PMID 19805492"},{"id":470759,"number":"PMID 21524432"},{"id":470791,"number":"PMID 35781021"},{"id":470724,"number":"PMID 11145067"},{"id":470751,"number":"PMID 17021177"},{"id":470748,"number":"PMID 35940310"},{"id":470750,"number":"PMID 24966833"},{"id":470743,"number":"PMID 21514249"},{"id":470712,"number":"PMID 19151162"},{"id":470778,"number":"PMID 28416048"},{"id":470733,"number":"PMID 11747573"},{"id":470783,"number":"PMID 12483214"},{"id":470762,"number":"PMID 36820052"},{"id":470794,"number":"PMID 28089351"},{"id":470777,"number":"PMID 19853042"},{"id":470730,"number":"PMID 15356639"},{"id":470752,"number":"PMID 28235679"},{"id":470739,"number":"PMID 17630048"},{"id":470709,"number":"PMID 16207622"},{"id":470798,"number":"PMID 27981671"},{"id":470793,"number":"PMID 26082014"},{"id":470792,"number":"PMID 34563876"},{"id":470717,"number":"PMID 15118552"},{"id":470731,"number":"PMID 21325651"},{"id":470779,"number":"PMID 30879030"},{"id":470802,"number":"PMID 24798886"},{"id":470729,"number":"PMID 28384471"},{"id":470784,"number":"PMID 19467352"},{"id":470734,"number":"PMID 34610518"},{"id":470769,"number":"PMID 34052810"},{"id":470741,"number":"PMID 14610120"},{"id":470740,"number":"PMID 32278267"},{"id":470699,"number":"PMID 32738937"},{"id":470738,"number":"PMID 12061414"},{"id":470801,"number":"PMID 20226489"},{"id":470771,"number":"PMID 18675053"},{"id":470710,"number":"PMID 21325523"},{"id":470696,"number":"PMID 22179485"},{"id":470786,"number":"PMID 10659083"},{"id":470763,"number":"PMID 31413319"},{"id":470756,"number":"PMID 26402076"},{"id":470720,"number":"PMID 16682675"},{"id":470698,"number":"PMID 11571040"},{"id":470753,"number":"PMID 22496200"},{"id":470693,"number":"PMID 29194503"},{"id":470795,"number":"PMID 20159444"},{"id":470725,"number":"PMID 14977420"},{"id":470727,"number":"PMID 12244076"},{"id":470764,"number":"PMID 35908534"},{"id":470706,"number":"PMID 31785046"},{"id":470765,"number":"PMID 15070770"},{"id":470694,"number":"PMID 35949423"},{"id":470781,"number":"PMID 35576829"},{"id":470722,"number":"PMID 24656258"},{"id":470716,"number":"PMID 23110764"},{"id":470768,"number":"PMID 21545773"},{"id":470715,"number":"PMID 28279356"},{"id":470713,"number":"PMID 24018302"},{"id":470732,"number":"PMID 27825022"},{"id":470766,"number":"PMID 17511749"},{"id":470797,"number":"PMID 25108034"},{"id":470782,"number":"PMID 29053874"},{"id":470800,"number":"PMID 31822997"},{"id":470704,"number":"PMID 11438246"},{"id":470803,"number":"PMID 33667416"},{"id":470745,"number":"PMID 25873017"},{"id":470726,"number":"PMID 26076919"},{"id":470807,"number":"PMID 26378880"},{"id":470714,"number":"PMID 33313963"},{"id":470742,"number":"PMID 34024824"},{"id":470785,"number":"PMID 21156826"},{"id":470767,"number":"PMID 24336875"},{"id":470774,"number":"PMID 35970419"},{"id":470691,"number":"PMID 34774712"},{"id":470775,"number":"PMID 21514250"},{"id":470697,"number":"PMID 30387527"},{"id":470721,"number":"PMID 11716055"},{"id":470805,"number":"PMID 21710360"},{"id":470744,"number":"PMID 32241955"},{"id":470735,"number":"PMID 19936229"},{"id":470788,"number":"PMID 18675054"},{"id":470799,"number":"PMID 22922563"},{"id":470692,"number":"PMID 12821520"},{"id":470736,"number":"PMID 31837086"},{"id":470705,"number":"PMID 26306871"},{"id":470758,"number":"PMID 37193409"},{"id":470804,"number":"PMID 33418092"},{"id":470787,"number":"PMID 14608034"},{"id":470757,"number":"PMID 19428409"},{"id":470772,"number":"PMID 35037569"},{"id":470761,"number":"PMID 37176588"},{"id":470728,"number":"PMID 36281687"},{"id":470723,"number":"PMID 24366271"},{"id":470700,"number":"PMID 16945915"},{"id":470702,"number":"PMID 28364458"},{"id":470737,"number":"PMID 29475810"},{"id":470718,"number":"PMID 27447979"}],"pubmedCode":["PMID 28592453","PMID 33986301","PMID 35841910","PMID 20592579","PMID 20212064","PMID 20046194","PMID 29504542","PMID 11413257","PMID 24179859","PMID 24304757","PMID 29901881","PMID 34560904","PMID 24846773","PMID 36653245","PMID 14694035","PMID 33100995","PMID 19779148","PMID 35575089","PMID 28757454","PMID 22119654","PMID 19805492","PMID 21524432","PMID 35781021","PMID 11145067","PMID 17021177","PMID 35940310","PMID 24966833","PMID 21514249","PMID 19151162","PMID 28416048","PMID 11747573","PMID 12483214","PMID 36820052","PMID 28089351","PMID 19853042","PMID 15356639","PMID 28235679","PMID 17630048","PMID 16207622","PMID 27981671","PMID 26082014","PMID 34563876","PMID 15118552","PMID 21325651","PMID 30879030","PMID 24798886","PMID 28384471","PMID 19467352","PMID 34610518","PMID 34052810","PMID 14610120","PMID 32278267","PMID 32738937","PMID 12061414","PMID 20226489","PMID 18675053","PMID 21325523","PMID 22179485","PMID 10659083","PMID 31413319","PMID 26402076","PMID 16682675","PMID 11571040","PMID 22496200","PMID 29194503","PMID 20159444","PMID 14977420","PMID 12244076","PMID 35908534","PMID 31785046","PMID 15070770","PMID 35949423","PMID 35576829","PMID 24656258","PMID 23110764","PMID 21545773","PMID 28279356","PMID 24018302","PMID 27825022","PMID 17511749","PMID 25108034","PMID 29053874","PMID 31822997","PMID 11438246","PMID 33667416","PMID 25873017","PMID 26076919","PMID 26378880","PMID 33313963","PMID 34024824","PMID 21156826","PMID 24336875","PMID 35970419","PMID 34774712","PMID 21514250","PMID 30387527","PMID 11716055","PMID 21710360","PMID 32241955","PMID 19936229","PMID 18675054","PMID 22922563","PMID 12821520","PMID 31837086","PMID 26306871","PMID 37193409","PMID 33418092","PMID 14608034","PMID 19428409","PMID 35037569","PMID 37176588","PMID 36281687","PMID 24366271","PMID 16945915","PMID 28364458","PMID 29475810","PMID 27447979"],"pubmedUrl":["https://pubmed.ncbi.nlm.nih.gov/28592453","https://pubmed.ncbi.nlm.nih.gov/33986301","https://pubmed.ncbi.nlm.nih.gov/35841910","https://pubmed.ncbi.nlm.nih.gov/20592579","https://pubmed.ncbi.nlm.nih.gov/20212064","https://pubmed.ncbi.nlm.nih.gov/20046194","https://pubmed.ncbi.nlm.nih.gov/29504542","https://pubmed.ncbi.nlm.nih.gov/11413257","https://pubmed.ncbi.nlm.nih.gov/24179859","https://pubmed.ncbi.nlm.nih.gov/24304757","https://pubmed.ncbi.nlm.nih.gov/29901881","https://pubmed.ncbi.nlm.nih.gov/34560904","https://pubmed.ncbi.nlm.nih.gov/24846773","https://pubmed.ncbi.nlm.nih.gov/36653245","https://pubmed.ncbi.nlm.nih.gov/14694035","https://pubmed.ncbi.nlm.nih.gov/33100995","https://pubmed.ncbi.nlm.nih.gov/19779148","https://pubmed.ncbi.nlm.nih.gov/35575089","https://pubmed.ncbi.nlm.nih.gov/28757454","https://pubmed.ncbi.nlm.nih.gov/22119654","https://pubmed.ncbi.nlm.nih.gov/19805492","https://pubmed.ncbi.nlm.nih.gov/21524432","https://pubmed.ncbi.nlm.nih.gov/35781021","https://pubmed.ncbi.nlm.nih.gov/11145067","https://pubmed.ncbi.nlm.nih.gov/17021177","https://pubmed.ncbi.nlm.nih.gov/35940310","https://pubmed.ncbi.nlm.nih.gov/24966833","https://pubmed.ncbi.nlm.nih.gov/21514249","https://pubmed.ncbi.nlm.nih.gov/19151162","https://pubmed.ncbi.nlm.nih.gov/28416048","https://pubmed.ncbi.nlm.nih.gov/11747573","https://pubmed.ncbi.nlm.nih.gov/12483214","https://pubmed.ncbi.nlm.nih.gov/36820052","https://pubmed.ncbi.nlm.nih.gov/28089351","https://pubmed.ncbi.nlm.nih.gov/19853042","https://pubmed.ncbi.nlm.nih.gov/15356639","https://pubmed.ncbi.nlm.nih.gov/28235679","https://pubmed.ncbi.nlm.nih.gov/17630048","https://pubmed.ncbi.nlm.nih.gov/16207622","https://pubmed.ncbi.nlm.nih.gov/27981671","https://pubmed.ncbi.nlm.nih.gov/26082014","https://pubmed.ncbi.nlm.nih.gov/34563876","https://pubmed.ncbi.nlm.nih.gov/15118552","https://pubmed.ncbi.nlm.nih.gov/21325651","https://pubmed.ncbi.nlm.nih.gov/30879030","https://pubmed.ncbi.nlm.nih.gov/24798886","https://pubmed.ncbi.nlm.nih.gov/28384471","https://pubmed.ncbi.nlm.nih.gov/19467352","https://pubmed.ncbi.nlm.nih.gov/34610518","https://pubmed.ncbi.nlm.nih.gov/34052810","https://pubmed.ncbi.nlm.nih.gov/14610120","https://pubmed.ncbi.nlm.nih.gov/32278267","https://pubmed.ncbi.nlm.nih.gov/32738937","https://pubmed.ncbi.nlm.nih.gov/12061414","https://pubmed.ncbi.nlm.nih.gov/20226489","https://pubmed.ncbi.nlm.nih.gov/18675053","https://pubmed.ncbi.nlm.nih.gov/21325523","https://pubmed.ncbi.nlm.nih.gov/22179485","https://pubmed.ncbi.nlm.nih.gov/10659083","https://pubmed.ncbi.nlm.nih.gov/31413319","https://pubmed.ncbi.nlm.nih.gov/26402076","https://pubmed.ncbi.nlm.nih.gov/16682675","https://pubmed.ncbi.nlm.nih.gov/11571040","https://pubmed.ncbi.nlm.nih.gov/22496200","https://pubmed.ncbi.nlm.nih.gov/29194503","https://pubmed.ncbi.nlm.nih.gov/20159444","https://pubmed.ncbi.nlm.nih.gov/14977420","https://pubmed.ncbi.nlm.nih.gov/12244076","https://pubmed.ncbi.nlm.nih.gov/35908534","https://pubmed.ncbi.nlm.nih.gov/31785046","https://pubmed.ncbi.nlm.nih.gov/15070770","https://pubmed.ncbi.nlm.nih.gov/35949423","https://pubmed.ncbi.nlm.nih.gov/35576829","https://pubmed.ncbi.nlm.nih.gov/24656258","https://pubmed.ncbi.nlm.nih.gov/23110764","https://pubmed.ncbi.nlm.nih.gov/21545773","https://pubmed.ncbi.nlm.nih.gov/28279356","https://pubmed.ncbi.nlm.nih.gov/24018302","https://pubmed.ncbi.nlm.nih.gov/27825022","https://pubmed.ncbi.nlm.nih.gov/17511749","https://pubmed.ncbi.nlm.nih.gov/25108034","https://pubmed.ncbi.nlm.nih.gov/29053874","https://pubmed.ncbi.nlm.nih.gov/31822997","https://pubmed.ncbi.nlm.nih.gov/11438246","https://pubmed.ncbi.nlm.nih.gov/33667416","https://pubmed.ncbi.nlm.nih.gov/25873017","https://pubmed.ncbi.nlm.nih.gov/26076919","https://pubmed.ncbi.nlm.nih.gov/26378880","https://pubmed.ncbi.nlm.nih.gov/33313963","https://pubmed.ncbi.nlm.nih.gov/34024824","https://pubmed.ncbi.nlm.nih.gov/21156826","https://pubmed.ncbi.nlm.nih.gov/24336875","https://pubmed.ncbi.nlm.nih.gov/35970419","https://pubmed.ncbi.nlm.nih.gov/34774712","https://pubmed.ncbi.nlm.nih.gov/21514250","https://pubmed.ncbi.nlm.nih.gov/30387527","https://pubmed.ncbi.nlm.nih.gov/11716055","https://pubmed.ncbi.nlm.nih.gov/21710360","https://pubmed.ncbi.nlm.nih.gov/32241955","https://pubmed.ncbi.nlm.nih.gov/19936229","https://pubmed.ncbi.nlm.nih.gov/18675054","https://pubmed.ncbi.nlm.nih.gov/22922563","https://pubmed.ncbi.nlm.nih.gov/12821520","https://pubmed.ncbi.nlm.nih.gov/31837086","https://pubmed.ncbi.nlm.nih.gov/26306871","https://pubmed.ncbi.nlm.nih.gov/37193409","https://pubmed.ncbi.nlm.nih.gov/33418092","https://pubmed.ncbi.nlm.nih.gov/14608034","https://pubmed.ncbi.nlm.nih.gov/19428409","https://pubmed.ncbi.nlm.nih.gov/35037569","https://pubmed.ncbi.nlm.nih.gov/37176588","https://pubmed.ncbi.nlm.nih.gov/36281687","https://pubmed.ncbi.nlm.nih.gov/24366271","https://pubmed.ncbi.nlm.nih.gov/16945915","https://pubmed.ncbi.nlm.nih.gov/28364458","https://pubmed.ncbi.nlm.nih.gov/29475810","https://pubmed.ncbi.nlm.nih.gov/27447979"]},"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-12-19","conclusionDate":"2025-12-19","therapeuticAreas":[{"code":"33","name":"Psychiatry and Psychology [F] - Mental Disorders [F03]"},{"code":"28","name":"Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Investigative Techniques [E05]"},{"code":"23","name":"Diseases [C] - Pathological Conditions, Signs and Symptoms [C23]"}],"medicalConditions":[{"id":115505,"medicalCondition":"Semantic Variant Primary Progressive Aphasia","isConditionRareDisease":false},{"id":115504,"medicalCondition":"Alcohol Use Disorder","isConditionRareDisease":false},{"id":115503,"medicalCondition":"Organic amnesia syndrome","isConditionRareDisease":false},{"id":115507,"medicalCondition":"Narcolepsy","isConditionRareDisease":false},{"id":115506,"medicalCondition":"Alzheimer","isConditionRareDisease":false},{"id":115508,"medicalCondition":"Lewy Body Dementia","isConditionRareDisease":false}],"sponsors":[{"id":125385,"primary":true,"publicContacts":[{"id":370185,"type":"Public","functionalName":"scientific manager","functionalEmailAddress":"chetelat@cyceron.fr","telephone":"0231470173","organisation":{"id":844426,"type":"Laboratory/Research/Testing facility","typeCode":"9","name":"Institut National De La Sante Et De La Recherche Medicale","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100007463","organisationLocationStatus":"Active"}}],"scientificContacts":[{"id":370186,"type":"Scientific","functionalName":"scientific manager","functionalEmailAddress":"chetelat@cyceron.fr","telephone":"0231470173","organisation":{"id":844426,"type":"Laboratory/Research/Testing facility","typeCode":"9","name":"Institut National De La Sante Et De La Recherche Medicale","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100007463","organisationLocationStatus":"Active"}}],"thirdParties":[{"id":558350,"organisationAddress":{"id":835851,"organisation":{"id":877147,"type":"Pharmaceutical company","typeCode":"10","name":"Petnet Solutions S.A.S.","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100012541","organisationLocationStatus":"Active"},"address":{"addressId":928618,"oneLine":"Zac Du Bois Chaland, 15 Rue Des Pyrenees","addressLine1":"Zac Du Bois Chaland","addressLine2":"15 Rue Des Pyrenees","addressLine3":"","addressLine4":"","city":"Lisses","postcode":"91090","country":2012,"countryName":"France"},"phone":"0178054040","email":"commandes.petnetfrance.fr@siemens-healthineers.com","isBusinessKeyValidated":true,"businessKey":"ORG-100012541"},"sponsorDuties":[{"id":868894,"code":"14"}],"phoneNumber":"0178054040","email":"commandes.petnetfrance.fr@siemens-healthineers.com"},{"id":558351,"organisationAddress":{"id":835849,"organisation":{"id":877145,"type":"Pharmaceutical company","typeCode":"10","name":"Curium Pet France","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100001208","organisationLocationStatus":"Active"},"address":{"addressId":928616,"oneLine":"14 Rue De La Grange Aux Belles","addressLine1":"14 Rue De La Grange Aux Belles","addressLine2":"","addressLine3":"","addressLine4":"","city":"Paris","postcode":"75010","country":2012,"countryName":"France"},"phone":"0473646427","email":"commandes.pet@curiumpharma.com","isBusinessKeyValidated":true,"businessKey":"ORG-100001208"},"sponsorDuties":[{"id":868895,"code":"14"}],"phoneNumber":"0473646427","email":"commandes.pet@curiumpharma.com"}],"organisation":{"id":844426,"type":"Laboratory/Research/Testing facility","typeCode":"9","name":"Institut National De La Sante Et De La Recherche Medicale","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100007463","organisationLocationStatus":"Active"},"addresses":[{"id":805140,"organisation":{"id":844426,"type":"Laboratory/Research/Testing facility","typeCode":"9","name":"Institut National De La Sante Et De La Recherche Medicale","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100007463","organisationLocationStatus":"Active"},"address":{"addressId":891086,"oneLine":"101 Rue De Tolbiac","addressLine1":"101 Rue De Tolbiac","addressLine2":"","addressLine3":"","addressLine4":"","city":"Paris","postcode":"75013","country":2012,"countryName":"France"},"isBusinessKeyValidated":true,"businessKey":"ORG-100007463"}],"isCommercial":false,"commercial":"Non-Commercial"}],"trialCategoryCode":"2","trialCategoryJustificationComment":"physiopathological study using products outside the conditions of their marketing authorization (memory disorders including healthy volunteers)","partOneTherapeuticAreas":[{"id":1040485,"therapeuticArea":{"code":"33","name":"Psychiatry and Psychology [F] - Mental Disorders [F03]"}},{"id":1040486,"therapeuticArea":{"code":"28","name":"Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Investigative Techniques [E05]"}},{"id":1040487,"therapeuticArea":{"code":"23","name":"Diseases [C] - Pathological Conditions, Signs and Symptoms [C23]"}}],"productRoleGroupInfos":[{"id":345874,"comments":"FLORTAUCIPIR (18F), FLORTAUCIPIR (18F)","productRoleCode":"1","productRoleName":"Test","products":[{"id":461513,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB194115","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"FLORTAUCIPIR (18F)","pharmForm":"SOLUTION FOR INJECTION","activeSubstanceName":"FLORTAUCIPIR (18F)","euSubstNumber":"SUB194115","productSubstances":[{"substancePk":"338079","actSubstOrigin":"Chemical","actSubstName":"FLORTAUCIPIR (18F)","substanceEvCode":"SUB194115"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"MBq megabecquerel(s)","maxDailyDoseAmount":"370","doseUomTotal":"MBq megabecquerel(s)","maxTotalDoseAmount":"370","productChangedRelationMA":true,"productChangeDescription":"use in volunteers","maxTreatmentPeriod":1,"timeUnitCode":"1","scientificProductEvCode":"SUB194115","devices":[],"characteristics":["3"],"routes":["INTRAVENOUS USE"],"allSubstancesChemicals":false,"productName":"FLORTAUCIPIR (18F)","jsonActiveSubstanceNames":"flortaucipir (18f)"},{"id":461514,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB194115","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"FLORTAUCIPIR (18F)","pharmForm":"SOLUTION FOR INJECTION","activeSubstanceName":"FLORTAUCIPIR (18F)","euSubstNumber":"SUB194115","productSubstances":[{"substancePk":"425488","actSubstOrigin":"Chemical","actSubstName":"FLORTAUCIPIR (18F)","substanceEvCode":"SUB194115"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"MBq megabecquerel(s)","maxDailyDoseAmount":"370","doseUomTotal":"MBq megabecquerel(s)","maxTotalDoseAmount":"370","productChangedRelationMA":true,"productChangeDescription":"use in volunteers","maxTreatmentPeriod":1,"timeUnitCode":"1","scientificProductEvCode":"SUB194115","devices":[],"characteristics":["3"],"routes":["INTRAVENOUS USE"],"allSubstancesChemicals":false,"productName":"FLORTAUCIPIR (18F)","jsonActiveSubstanceNames":"flortaucipir (18f)"}]},{"id":345875,"comments":"FLORBETAPIR (18F), FLORBETAPIR (18F)","productRoleCode":"1","productRoleName":"Test","products":[{"id":461515,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB33779","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"FLORBETAPIR (18F)","pharmForm":"SOLUTION FOR INJECTION","activeSubstanceName":"FLORBETAPIR (18F)","euSubstNumber":"SUB33779","productSubstances":[{"substancePk":"354897","actSubstOrigin":"Chemical","actSubstName":"FLORBETAPIR (18F)","substanceEvCode":"SUB33779"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"MBq megabecquerel(s)","maxDailyDoseAmount":"370","doseUomTotal":"MBq megabecquerel(s)","maxTotalDoseAmount":"370","productChangedRelationMA":true,"productChangeDescription":"use in volunteers","maxTreatmentPeriod":1,"timeUnitCode":"1","scientificProductEvCode":"SUB33779","devices":[],"characteristics":["3"],"routes":["INTRAVENOUS USE"],"allSubstancesChemicals":false,"productName":"FLORBETAPIR (18F)","jsonActiveSubstanceNames":"florbetapir (18f)"},{"id":461516,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB33779","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"FLORBETAPIR (18F)","pharmForm":"SOLUTION FOR INJECTION","activeSubstanceName":"FLORBETAPIR (18F)","euSubstNumber":"SUB33779","productSubstances":[{"substancePk":"157591","actSubstOrigin":"Chemical","actSubstName":"FLORBETAPIR (18F)","substanceEvCode":"SUB33779"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"MBq megabecquerel(s)","maxDailyDoseAmount":"370","maxTotalDoseAmount":"370","productChangedRelationMA":true,"productChangeDescription":"use in volunteers","maxTreatmentPeriod":1,"timeUnitCode":"1","scientificProductEvCode":"SUB33779","devices":[],"characteristics":["3"],"routes":["INTRAVENOUS USE"],"allSubstancesChemicals":false,"productName":"FLORBETAPIR (18F)","jsonActiveSubstanceNames":"florbetapir (18f)"}]}],"isLowIntervention":false},"authorizedPartsII":[{"id":271013,"mscId":53057,"mscInfo":{"id":53057,"clinicalTrialId":24934,"countryOrganisationId":2012,"reportingStatusCode":"Authorised","fromDate":"2026-01-12","toDate":"2026-01-12","isProposedRms":true,"countryName":"France","organisationInfo":{},"firstDecisionDate":"2026-01-23","trialStatus":"Authorised","trialPeriod":[{"id":83609,"trialStartDate":"2026-06-04","fromDate":"2026-06-05"},{"id":83610,"trialStartDate":"2026-06-04","fromDate":"2026-06-05"}],"trialRecruitmentPeriod":[{"id":113153,"recruitmentStartDate":"2026-06-04","fromDate":"2026-06-05"},{"id":113154,"recruitmentStartDate":"2026-06-04","fromDate":"2026-06-05"}],"hasRecruitmentStarted":true,"activeTrialPeriod":{"id":137514,"trialStartDate":"2026-06-04","fromDate":"2026-06-05"},"activeTrialRecruitmentPeriod":{"recruitmentStartDate":"2026-06-04"},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":261239,"mscId":53057,"trialStatus":"Authorised","trialStatusDate":"2026-01-23T18:35:26.613"},{"id":102009,"mscId":53057,"trialStatus":"Under evaluation","trialStatusDate":"2025-10-10T12:23:46.031"}],"applicationTypeMsc":"1","mscName":"France","assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-01-20","decision":"authorized","decisionDate":"2026-01-23"},"decisionDate":"2026-01-23","recruitmentSubjectCount":600,"trialSites":[{"id":1857146,"organisationAddressInfo":{"id":835145,"organisation":{"id":876436,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Centre Hospitalier Universitaire De Caen Normandie","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100006421","organisationLocationStatus":"Active"},"address":{"addressId":927765,"oneLine":"Avenue De La Cote De Nacre","addressLine1":"Avenue De La Cote De Nacre","addressLine2":"","addressLine3":"","addressLine4":"","city":"Caen","postcode":"14000","country":2012,"countryName":"France"},"phone":"0231064617","email":"martinaud-o@chu-caen.fr","isBusinessKeyValidated":true,"businessKey":"ORG-100006421"},"personInfo":{"id":2063962,"firstName":"Olivier","lastName":"Martinaud","telephone":"0231064617","email":"martinaud-o@chu-caen.fr"},"departmentName":"Centre de Recherche Clinique (CRC)"},{"id":1857142,"organisationAddressInfo":{"id":835115,"organisation":{"id":876406,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Centre Hospitalier Universitaire De Caen Normandie","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100006421","organisationLocationStatus":"Active"},"address":{"addressId":927731,"oneLine":"Avenue De La Cote De Nacre","addressLine1":"Avenue De La Cote De Nacre","addressLine2":"","addressLine3":"","addressLine4":"","city":"Caen","postcode":"14000","country":2012,"countryName":"France"},"phone":"0231064617","email":"martinaud-o@chu-caen.fr","isBusinessKeyValidated":true,"businessKey":"ORG-100006421"},"personInfo":{"id":2063958,"firstName":"Olivier","lastName":"Martinaud","telephone":"0231064617","email":"martinaud-o@chu-caen.fr"},"departmentName":"service de neurologie"},{"id":1857145,"organisationAddressInfo":{"id":835151,"organisation":{"id":876442,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Centre Hospitalier Universitaire De Caen Normandie","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100006421","organisationLocationStatus":"Active"},"address":{"addressId":927771,"oneLine":"Avenue De La Cote De Nacre","addressLine1":"Avenue De La Cote De Nacre","addressLine2":"","addressLine3":"","addressLine4":"","city":"Caen","postcode":"14000","country":2012,"countryName":"France"},"phone":"0231272495","email":"bertran-f@chu-caen.fr","isBusinessKeyValidated":true,"businessKey":"ORG-100006421"},"personInfo":{"id":2063961,"firstName":"Francoise","lastName":"Bertran","telephone":"0231272495","email":"bertran-f@chu-caen.fr"},"departmentName":"Service d’Exploration et de Traitement des Troubles du Sommeil"},{"id":1857141,"organisationAddressInfo":{"id":836048,"organisation":{"id":877344,"type":"Health care","typeCode":"2","name":"Groupement d'Interet public CYCERON","commercial":false,"isBusinessKeyValidated":false,"businessKey":"ORL-000016008","organisationLocationStatus":"Active"},"address":{"addressId":928840,"oneLine":"Boulevard Henri Becquerel, Campus Jules Horowitz","addressLine1":"Boulevard Henri Becquerel","addressLine2":"Campus Jules Horowitz","addressLine3":"","addressLine4":"","city":"Caen","postcode":"14000","country":2012,"countryName":"France"},"phone":"0231470136","email":"martinaud-o@chu-caen.fr","isBusinessKeyValidated":false,"businessKey":"ORL-000016008"},"personInfo":{"id":2063957,"firstName":"Olivier","lastName":"Martinaud","telephone":"0231470136","email":"martinaud-o@chu-caen.fr"},"departmentName":"Lieu de recherches impliquant la personne humaine (LRIPH Cyceron)"},{"id":1857143,"organisationAddressInfo":{"id":835144,"organisation":{"id":876435,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Centre Hospitalier Universitaire De Caen Normandie","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100006421","organisationLocationStatus":"Active"},"address":{"addressId":927764,"oneLine":"Avenue De La Cote De Nacre","addressLine1":"Avenue De La Cote De Nacre","addressLine2":"","addressLine3":"","addressLine4":"","city":"Caen","postcode":"14000","country":2012,"countryName":"France"},"phone":"0231064617","email":"martinaud-o@chu-caen.fr","isBusinessKeyValidated":true,"businessKey":"ORG-100006421"},"personInfo":{"id":2063959,"firstName":"Olivier","lastName":"Martinaud","telephone":"0231064617","email":"martinaud-o@chu-caen.fr"},"departmentName":"Centre Mémoire de Ressource et de Recherche (CMRR) de Basse-Normandie"},{"id":1857144,"organisationAddressInfo":{"id":835149,"organisation":{"id":876440,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Centre Hospitalier Universitaire De Caen Normandie","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100006421","organisationLocationStatus":"Active"},"address":{"addressId":927769,"oneLine":"Avenue De La Cote De Nacre","addressLine1":"Avenue De La Cote De Nacre","addressLine2":"","addressLine3":"","addressLine4":"","city":"Caen","postcode":"14000","country":2012,"countryName":"France"},"phone":"0231063106","email":"cabe-n@chu-caen.fr","isBusinessKeyValidated":true,"businessKey":"ORG-100006421"},"personInfo":{"id":2063960,"firstName":"Nicolas","lastName":"Cabé","telephone":"0231063106","email":"cabe-n@chu-caen.fr"},"departmentName":"Service d'addictologie"}],"applicationStatusCode":"Authorised"}],"applicationInfo":[{"id":61171,"type":"INITIAL","status":"Authorised","ctNumber":"2025-523264-21-00","trialStatus":"Authorised","submissionDate":"2025-10-10","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-12-19"},"partIIInfo":[{"id":271013,"mscId":53057,"mscInfo":{"id":53057,"mscName":"France","countryOrganisationId":2012,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-01-20","decision":"authorized","decisionDate":"2026-01-23","reportingStatusCode":"Authorised","countryName":"France","trialStatus":"Authorised","firstDecisionDate":"2026-01-23"},"applicationStatusCode":"Authorised"}],"decisionDate":"2026-01-23","ctMSCsByApplication":[{"id":53057,"mscName":"France","reportingStatusCode":"Authorised"}],"businessKey":"IN","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":106379,"applicationId":61171,"mscId":53057,"mscName":"France","decisionDate":"2026-01-23T18:35:27.022","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":271013,"part1Id":111323,"applicationType":"INITIAL","isRMS":true}],"productRoleGroupDocument":[{"documentUuid":"1e1836f9-0c95-45cf-92fc-cc64cb6e3f7c","productRoleGroupId":345874},{"documentUuid":"56953f83-1f81-470d-be1a-43c7e6586318","productRoleGroupId":345875}]}],"trialGlobalEnd":[],"memberStatesConcerned":[{"mscName":"France","mscId":53057,"firstDecisionDate":"2026-01-23T18:35:27.022","lastDecisionDate":"2026-01-23T18:35:27.022","mscPublicStatusCode":4}],"eudraCt":{"isTransitioned":false}},"events":{"temporaryHaltList":[],"trialEvents":[{"mscId":53057,"mscName":"France","events":[{"notificationType":"START_OF_TRIAL","date":"2026-06-04"},{"notificationType":"START_OF_RECRUITMENT","date":"2026-06-04"}]}],"unexpectedEvents":[],"seriousBreaches":[],"urgentSafetyMeasures":[]},"results":{},"documents":[{"title":"D1_Protocol 2025-523264-21-00","uuid":"04f52daf-e70d-4c27-b810-a203e41f5dab","documentType":"104","documentTypeLabel":"Protocol (for publication)","fileType":"PDF","associatedEntityId":111323,"manualVersion":"2","systemVersion":"2"},{"title":"D4_Patient facing documents_Carte participant","uuid":"a23bbe2f-a959-47a2-89c8-235eb930a397","documentType":"104","documentTypeLabel":"Protocol (for publication)","fileType":"PDF","associatedEntityId":111323,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient facing documents_Echelles et Questionnaires","uuid":"f42951f5-a945-4192-8be1-aebf95b5eb17","documentType":"104","documentTypeLabel":"Protocol (for publication)","fileType":"PDF","associatedEntityId":111323,"manualVersion":"1","systemVersion":"1"},{"title":"C24-50_Protocol 2025-523264-21-00 TC","uuid":"48403a6d-1f3b-43c4-9925-65af5bf34482","documentType":"104","documentTypeLabel":"Protocol (for publication)","fileType":"PDF","associatedEntityId":111323,"manualVersion":"2","systemVersion":"1"},{"title":"D1_Protocol synopsis FR 2025-523264-21-00","uuid":"54961ea2-c50e-41e4-a4ae-f02da687d22c","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","fileType":"PDF","associatedEntityId":111323,"manualVersion":"2","systemVersion":"2"},{"title":"C24-50_Protocol synopsis FR 2025-523264-21-00 TC","uuid":"45e6b60c-3e3c-4fe2-b9c6-504d3a4fdf43","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","fileType":"PDF","associatedEntityId":111323,"manualVersion":"2","systemVersion":"1"},{"title":"E2_SmPC TAUVID_20241203","uuid":"1e1836f9-0c95-45cf-92fc-cc64cb6e3f7c","documentType":"19","documentTypeLabel":"Summary of Product Characteristics (SmPC) (for publication)","fileType":"PDF","associatedEntityId":345874,"manualVersion":"1","systemVersion":"1"},{"title":"E2_SmPC AMYVID_20241021","uuid":"56953f83-1f81-470d-be1a-43c7e6586318","documentType":"19","documentTypeLabel":"Summary of Product Characteristics (SmPC) (for publication)","fileType":"PDF","associatedEntityId":345875,"manualVersion":"1","systemVersion":"1"},{"title":"K1_Recruitment arrangements","uuid":"efa3dcbe-1489-43a6-b1cd-25958f1dfad8","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","fileType":"PDF","associatedEntityId":271013,"manualVersion":"1","systemVersion":"1"},{"title":"K2_document_additionnel_ctr1","uuid":"3a97e689-cf80-44f4-8153-1e2707174bb2","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","fileType":"PDF","associatedEntityId":271013,"manualVersion":"1","systemVersion":"1"},{"title":"L1_SIS and ICF Informant","uuid":"ac844420-6181-416d-b68a-be4464053bc7","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","fileType":"PDF","associatedEntityId":271013,"manualVersion":"2","systemVersion":"2"},{"title":"L1_SIS and ICF SCD MCI-AD","uuid":"d77d5a29-1f54-4317-b2c0-148daa684085","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","fileType":"PDF","associatedEntityId":271013,"manualVersion":"2","systemVersion":"2"},{"title":"L1_SIS and ICF HC","uuid":"fa6e1771-6871-4226-a0d5-edae7108d4c8","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","fileType":"PDF","associatedEntityId":271013,"manualVersion":"2","systemVersion":"2"},{"title":"L1_SIS and ICF Act ATHL","uuid":"a4d795e6-2923-432f-adcf-a00eaebc50af","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","fileType":"PDF","associatedEntityId":271013,"manualVersion":"2","systemVersion":"2"},{"title":"L1_SIS and ICF D-AD LBD svPPA AMN","uuid":"4262b99d-50ff-4f83-bc76-3dc473a284ff","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","fileType":"PDF","associatedEntityId":271013,"manualVersion":"2","systemVersion":"2"},{"title":"L1_SIS and ICF AUD","uuid":"c40695c6-c5ec-4bb6-aced-cd64e5dde587","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","fileType":"PDF","associatedEntityId":271013,"manualVersion":"2","systemVersion":"2"},{"title":"L1_SIS and ICF NARCO","uuid":"481f1b31-26e9-4fdf-af6f-7737b39c35bf","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","fileType":"PDF","associatedEntityId":271013,"manualVersion":"2","systemVersion":"2"},{"title":"L1_SIS and ICF tuteur_AUD","uuid":"8b6a6e71-3e61-44f8-a3a6-12aa41c8abd4","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","fileType":"PDF","associatedEntityId":271013,"manualVersion":"2","systemVersion":"2"},{"title":"L1_SIS and ICF tuteur_D-AD LBD svPPA AMN","uuid":"b6543588-ce1e-4042-a469-7c38ee4d70de","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","fileType":"PDF","associatedEntityId":271013,"manualVersion":"2","systemVersion":"2"},{"title":"L1_SIS D-AD LBD svPPA AMN","uuid":"17a737a9-9175-47ff-9264-5abc71873b00","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","fileType":"PDF","associatedEntityId":271013,"manualVersion":"2","systemVersion":"2"},{"title":"L1_SIS and ICF tuteur_SCD MCI-AD","uuid":"3babda36-08cd-409b-a68d-3f47bf00125f","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","fileType":"PDF","associatedEntityId":271013,"manualVersion":"2","systemVersion":"2"},{"title":"L2_other subject information material_PRESSE","uuid":"6050c643-f4c9-4c63-8ba0-c7bcff0b94b0","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","fileType":"PDF","associatedEntityId":271013,"manualVersion":"1","systemVersion":"1"},{"title":"L2_other subject information material_affiches","uuid":"e6db34f3-5dd7-4473-a900-d75359e00ad2","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","fileType":"PDF","associatedEntityId":271013,"manualVersion":"1","systemVersion":"1"},{"title":"L1_SIS and ICF NARCO_TC","uuid":"fd055969-31cc-4e8a-a28a-886636a9559e","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","fileType":"PDF","associatedEntityId":271013,"manualVersion":"2","systemVersion":"1"},{"title":"L1_SIS and ICF HC_TC","uuid":"5b29fb5b-0b1b-41f3-8052-551612846ac9","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","fileType":"PDF","associatedEntityId":271013,"manualVersion":"2","systemVersion":"1"},{"title":"L1_SIS D-AD LBD svPPA AMN_TC","uuid":"522b5d85-8cd9-4190-99d7-40d944eb4f50","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","fileType":"PDF","associatedEntityId":271013,"manualVersion":"2","systemVersion":"1"},{"title":"L1_SIS and ICF SCD MCI-AD_TC","uuid":"f65feff0-e632-475e-8368-5e66ccab676f","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","fileType":"PDF","associatedEntityId":271013,"manualVersion":"2","systemVersion":"1"},{"title":"L1_SIS and ICF D-AD LBD svPPA AMN_TC","uuid":"af6e7014-9527-4e0d-b59e-e890dd0468bd","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","fileType":"PDF","associatedEntityId":271013,"manualVersion":"2","systemVersion":"1"},{"title":"L1_SIS and ICF tuteur_AUD_TC","uuid":"f0ea2db5-62e8-488c-b560-6f5db66b18bf","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","fileType":"PDF","associatedEntityId":271013,"manualVersion":"2","systemVersion":"1"},{"title":"L1_SIS and ICF tuteur_SCD MCI-AD_TC","uuid":"73373795-ea6c-4256-be75-7c78e5d571d3","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","fileType":"PDF","associatedEntityId":271013,"manualVersion":"2","systemVersion":"1"},{"title":"L1_SIS and ICF tuteur_D-AD LBD svPPA AMN_TC","uuid":"cb268c53-83a9-4815-b3e7-82e2ecef64ff","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","fileType":"PDF","associatedEntityId":271013,"manualVersion":"2","systemVersion":"1"},{"title":"L1_SIS and ICF Act_ATHL_TC","uuid":"c5505b00-e31c-419e-83c6-42c37824de46","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","fileType":"PDF","associatedEntityId":271013,"manualVersion":"2","systemVersion":"1"},{"title":"L1_SIS and ICF AUD_TC","uuid":"fbcbe663-1697-4102-aa37-bf3e2a21173f","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","fileType":"PDF","associatedEntityId":271013,"manualVersion":"2","systemVersion":"1"},{"title":"L1_SIS and ICF Informant_TC","uuid":"ddd55115-7506-405f-9009-da75579a59ab","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","fileType":"PDF","associatedEntityId":271013,"manualVersion":"2","systemVersion":"1"}],"trialRegion":"EEA","trialRegionCode":1,"correctiveMeasures":[]}